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ABSTRACT 
 
 Oral consumption of flaxseed improves serum lipid parameters, and the flaxseed 
lignan, secoisolariciresinol diglucoside (SDG) may mediate these effects.  SDG’s 
therapeutic potential cannot be fully realized until its mechanism of action and 
pharmacokinetics are more completely characterized. 
 This research aimed to assess SDG’s effects in dietary models of 
hypertriglyceridemia, hypercholesterolemia, and obesity. Furthermore, this thesis work 
provided preliminary pharmacokinetic data on SDG’s aglycone form, secoisolariciresinol 
(SECO). 
 Dietary manipulations were used to induce hyperlipidemic states in female Wistar 
or male Sprague-Dawley rats. Groups of 10 rats were randomly assigned to one of three 
(obesity and cholesterol diets) or four (fructose) treatment groups: 1) Normal diet with 
0.0 µmol SDG/kg body weight; 2) Dietary manipulation with 0.0 µmol SDG/kg; 3) 
Dietary manipulation with 4.4 µmol SDG/kg; and 4) 10% fructose in water with 8.8 µmol 
SDG/kg. Lignan or vehicle (saline) was administered daily by oral gavage for four weeks 
(2 weeks for male Sprague-Dawleys). After four (or two) weeks of SDG administration, 
body and liver weights were recorded, serum lipids were measured using enzymatic kits, 
hepatic fat accumulation was determined by histochemical analysis and hepatic mRNA 
expression of triglyceride pathway targets was evaluated using real-time RT-PCR. A 10% 
fructose in water model was effective for the induction of hypertriglyceridemia in male 
Sprague-Dawley rats but ineffective in female Wistar rats of similar age. Neither 4.4 nor 
8.8 µmol SDG/kg improved serum and hepatic triglyceride parameters in male Sprague-
Dawley rats on a 10% fructose in water diet. It is suspected that gender and strain are 
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important factors for this model of hypertriglyceridemia.  Dietary manipulations for the 
induction of hypercholesterolemia and obesity in female Wistar rats were not effective 
following 4 weeks administration of a 1% cholesterol diet and a 45% fat diet 
respectively.  Since previous studies were able to successfully induce 
hypercholesterolemia in the same model, it is suspected that the differences in age of the 
animals accounted for the inconsistent results.  Strain, gender and age of animals were 
identified as important considerations when trying to induce hyperlipidemic states 
through dietary manipulations.   
 SDG (4.4 µmol/kg) dosed daily for four weeks caused no gross morphological 
organ changes or alterations in blood chemistry or hematology parameters. Following an 
intravenous bolus (10 mg/kg), secoisolariciresinol (SECO) disposition was consistent 
with two-compartment pharmacokinetics, with distribution and elimination half-lives at 
26 seconds and 5 minutes, respectively. No SECO was detected in the plasma following 
an oral bolus (10 mg/kg).   
 Further investigation into SDG’s hypolipidemic effects are required to elucidate 
its mechanism of action.  A complete pharmacokinetic study is warranted to fully 
understand SDG’s safety and efficacy.
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1. Literature Review 
1.1 Health Effects of Hyperlipidemia 
1.1.1 Hyperlipidemia as a Risk Factor for Cardiovascular Disease 
In the past several years, a great deal of information regarding the pathophysiology of 
cardiovascular disease (CVD) has been collected.  Hypertension, smoking, diabetes and 
obesity are various factors that contribute to the onset of CVD1,2. These conditions are 
often associated with hyperlipidemia and both hypercholesterolemia and 
hypertriglyceridemia are important independent risk factors for CVD3-7.  Much research 
on hyperlipidemia has sought to identify which lipid parameters are most closely 
correlated with an increased risk of CVD. Elevated serum total cholesterol and low-
density lipoprotein cholesterol (LDL-C) levels, low serum high-density lipoprotein 
cholesterol (HDL-C) levels, and high serum triglyceride (TG) levels have been correlated 
with increased incidences of CVD1,2,8,9.   
Traditional therapeutic strategies focus on the management of serum cholesterol 
levels as essential in the treatment of CVD. However, the increased awareness of 
triglyceride levels as an independent risk factor requires the additional consideration of 
therapeutic options to reduce serum triglycerides to decrease incidences of CVD.  Despite 
the identification of important risk factors for CVD, this disease remains the leading 
cause of death in Europe and the United States and is estimated to be the leading cause of 
death in all developing countries in the next decade10.  CVD remains the leading cause of 
death in Canada accounting for 37% of all deaths annually11.  The economic burden 
attributed to CVD each year is 7.3 billion dollars of total health care costs and 12.3 
billion of total indirect health care costs for all disease categories12.  Much more effective 
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therapeutic alternatives are required to halt the growing prevalence of this disease and its 
financial burden.  
 
1.1.2. Etiology of Hyperlipidemia 
 Hyperlipidemia occurs when the body is unable to control its pool of lipids to 
maintain levels within optimal physiological ranges13.  In CVD, the circulating lipids that 
have the largest impact are LDL-C, HDL-C and TG. Lifestyle (i.e. high fat diets)7 and 
genetic factors,14 various disease states2, and some medications15-17 are principle factors 
that contribute to hyperlipidemia.  
 Increased levels of serum lipids are not a cause of CVD, but only a risk factor18,19. 
Classification of high risk individuals includes those hyperlipidemic patients who show 
clinically evident atherosclerosis and diabetic individuals over the age of 3011.  Other 
factors that predispose individuals to a high CVD risk include; a family history of CVD, 
abdominal obesity, a body mass index above 25, a sedentary lifestyle, a postmenopausal 
state, ethnic background11 and the clinical phenotype of a “hypertriglyceridemic waist” 
(waist circumference of more than or equal to 90 cm and plasma triglyceride levels of 
177 mg/dL)2.  
Lifestyle factors, principally high fat/carbohydrate diets and lack of physical activity, 
lead to acquired hyperlipidemia20. Secondary causes of hyperlipidemia include disease 
states, such as hyperthyroidism, obesity, renal disease, diabetes, excessive alcohol intake, 
and medications that may affect lipid levels11. In particular, obesity and diabetes are often 
associated with hyperlipidemia in a condition known as metabolic syndrome, which is 
characterized by a low serum HDL-C and elevated TG levels, blood pressure and blood 
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glucose levels following a 12 hour fast8.  Patients with metabolic syndrome have 
significantly enhanced risk for CVD regardless of their LDL-C levels8 . 
Several important pharmacotherapeutic agents used in the treatment of serious, life-
threatening diseases may also lead to an acquired hyperlipidemia (often referred to as 
iatrogenic hyperlipidemia)21.  Examples include immunosuppressive drugs (e.g. 
corticosteroids and cyclosporin) and protease inhibitors (e.g. ritonavir)21. Almost 50% of 
individuals who receive protease-inhibitor treatment demonstrate hypercholesterolemia 
and hypertriglyceridemia after only 2 years15. For many patients, effective treatments for 
drug-induced hyperlipidemias are lacking, since many of the most effective 
hypolipidemic drugs often lead to serious drug-drug interactions when combined with 
protease inhibitors or immunosuppressants21.  For example, a drug-drug interaction often 
occurs when a statin is combined with cyclosporin, resulting in increased incidence of 
statin-induced toxicity21.   
Genetic factors may also lead to hyperlipidemia. For example, a genetic defect in the 
LDL receptor gene results in familial hypercholesterolemia (FH)20.  Tangiers disease is 
caused by an autosomal recessive mutation in the ATP-binding cassette transporter A1 
(ABCA1), an important protein involved in reverse cholesterol transport22. No treatment 
options exist today for Tangiers disease. 
 
1.2 Cholesterol and Triglyceride Homeostasis 
In general, the balance between lipid biosynthesis (or dietary uptake) and lipid 
clearance controls serum lipid concentrations. Hyperlipidemia usually follows from a 
disordered regulatory system that alters activity of the various proteins involved in lipid 
 3
metabolic pathways, thus disrupting the balance between lipid biosynthesis and 
clearance. Therapies designed to cause compensatory changes in the expression levels of 
key proteins of each lipid metabolic pathways or, alternatively, reverse the abnormal 
regulatory mechanisms through restoration of enzyme expression levels or activity within 
normal levels may resolve hyperlipidemic states. Possibly, the putative triglyceride- and 
cholesterol-lowering effects of flaxseed are likely achieved through several distinct 
mechanisms.  
Cholesterol is a critical structural component of all cells within the body and an 
important precursor of steroid hormones, vitamin D and bile acids. Total body cholesterol 
homeostasis is maintained by balancing dietary cholesterol intake, de novo synthesis and 
fecal excretion23. Cholesterol content is tightly regulated because there is no mammalian 
pathway that can utilize cholesterol as an energy source24, as opposed to fatty acids that 
are used as a recyclable energy storage form. 
 
1.2.1 Lipid Absorption 
 Cholesterol absorption begins in the stomach where dietary constituents are mixed 
with salivary and gastric enzymes25.  The stomach also regulates the delivery of the 
gastric chyme to the duodenum where it is mixed with bile and pancreatic juice.  In the 
small intestine, cholesterol depends on bile salt solutions to solubilize it in the aqueous 
environment26.  Bile salts act as a detergent and when mixed with phospholipids and 
monoacylglycerides, they are able to increase the solubility of cholesterol so that it can be 
incorporated into micelles13.   
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Before reaching the transporters on the intestinal lumen, cholesterol must pass 
through a diffusion barrier (mucous coat) located at the lumen membrane interface25.  
This unstirred water layer slows cholesterol absorption.  Micelles provide a transport 
vehicle for cholesterol to cross this layer toward the brush border of the small intestine 
where monomeric cholesterol can be taken up into the enterocytes26. 
There are various channels that reside on the luminal side of an enterocyte.  The 
Niemann-Pick C1 like protein (NPC1L1) is an uptake channel that brings cholesterol into 
the cell while the adenosine triphosphate-binding cassette (ABCG5/G8) complex pumps 
cholesterol and other noncholesterol sterols back into the lumen13,25.   
Once unesterified cholesterol reaches the small intestinal wall, it is rapidly sent to 
the endoplasmic reticulum to be processed.  In the endoplasmic reticulum, acyl-
CoA:cholesterol acyltransferase (ACAT) re-esterifies cholesterol while microsomal 
triglyceride transfer protein (MTP) transfers the new lipids into chylomicrons with the 
surface recognition protein apoB48 which are then exported into the intestinal lymph.   
Dietary fats provide an exogenous source of TG.  In the intestine, triglycerides are 
broken down into fatty acids and monoglycerides by pancreatic acids before being 
incorporated into micelles.  Following absorption into an enterocyte they are re-esterified 
by acyl-coenzyme A:diglycerol acyltransferase (DGAT) to form triglycerides.  In the 
enterocyte, triglycerides and cholesteryl esters along with a surface particle, apoB48 are 
brought together to form a chylomicron that is ready to be exocytosed into the lymph to 
eventually enter circulation.   Chylomicrons are transport packages made by enterocytic 
microsomal transfer protein and function to deliver triglycerides to muscle and adipose 
tissue in exchange for cholesterol absorbed from the intestine to be brought to the liver.   
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1.2.2 Biosynthesis and Regulation 
Figure 1.1 summarizes the key steps involved in the biosynthesis of cholesterol. 
 
2 acetyl-CoA 
acetoacetyl-CoA thiolase 
acetoacetyl-CoA 
HMG-CoA synthase 
HMG-CoA 
HMG-CoA reductase 
mevalonate 
mevalonate kinase 
5-phosphomevalonate 
phosphomevalonate kinase 
5-pyrophosphate mevalonate 
phosphomevalonate decarboxylase 
D3-isopentyl-pyrophosphate 
D3-isopentyl-pyrophosphate isomerase 
dimethylallyl pyrophosphate 
farnesyl-pyrophosphate transferase 
geranyl pyrophosphate 
farnesyl-pyrophosphate transferase 
farnesyl pyrophosphate 
squalene synthase 
squalene 
squalene epoxidase 
squalene 2,3-epoxide 
oxidosqualene cyclase
lanosterol 
cholesterol 
Figure 1.1 The biosynthetic pathway for cholesterol production in vivo. 
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Cholesterol biosynthesis occurs in the cytoplasm and microsomes of hepatocytes 
and enterocytes.  Cholesterol biosynthesis begins with the transport of acetyl-CoA from 
the mitochondria to the cytosol of the cell.  In the cytosol, two acetyl-CoA are converted 
into 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) by HMG-CoA synthase.  HMG-CoA 
is then converted to mevalonate by HMG-CoA reductase, which is found in the 
endoplasmic reticulum.  This is the rate-limiting step in the formation of cholesterol and 
HMG-CoA reductase is an enzyme that is subject to complex regulatory control.  
Mevalonate is then converted into isopentenyl-pyrophosphate which is then converted to 
squalene that is converted into cholesterol27.  The synthesis of cholesterol predominantly 
occurs in the liver but also to a lesser extent in extrahepatic tissues28.   
 Plasma cholesterol concentrations are regulated by the endogenous synthesis of 
cholesterol and exogenous absorption of dietary and biliary cholesterol28.  The body 
produces enough cholesterol to make up for cholesterol excreted in the feces but takes 
into consideration the dietary uptake of cholesterol.  Cholesterol itself acts as a feed back 
inhibitor for cholesterol production. 
The cellular regulation of cholesterol biosynthesis is mainly controlled by the 
regulation of HMG-CoA reductase activity with alterations in the activity of the enzyme 
resulting in proportional changes in cholesterol synthesis, and total serum cholesterol 
levels and inversely proportional changes in the LDL receptor, LDL catabolism and 
hepatic lipoprotein synthesis27.  Cholesterol levels control this enzyme as cholesterol 
itself acts as a feedback inhibitor for existing HMG-CoA reductase.  When there is excess 
cholesterol, it induces rapid degradation of the enzyme as well as decreasing the amount 
of mRNA for HMG-CoA reductase which leads to decreased expression of the enzyme29.   
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Cholesterol regulation of excess intracellular free cholesterol occurs by 
controlling the activity of ACAT, an enzyme that catalyzes the esterification of 
cholesterol and plays a role in intracellular cholesterol storage and hepatic lipoprotein 
assembly30.  Inhibition of this enzyme lowers serum cholesterol and triglyceride levels 
and reduces hepatic production of apolipoprotein B31. Further regulation of plasma 
cholesterol levels occurs through LDL-R mediated uptake and HDL-C mediated reverse 
transport. 
Two pathways are involved in TG biosynthesis3.  The first pathway is responsible 
for processing fat from the diet (exogenous cycle).  Triglycerides from dietary fat are 
transported to chylomicrons constructed in the intestinal cell (unless the free fatty acids in 
the TG are medium-chain FA or smaller, in which case they can be absorbed directly 
from the intestinal brush border cell to the portal vein circulation straight into the liver).  
These chylomicrons are a shuttle between the gut and portal blood, with the final 
destination being the liver.  Once in the liver, the lipoprotein particle’s triglyceride core is 
hydrolyzed to glycerol and free fatty acids, leaving behind a remnant particle. 
 The second cycle in TG biosynthesis involves the generation of lipoprotein 
particles bearing TG that are manufactured in the liver.  This endogenous cycle produces 
very low density lipoprotein (VLDL) particles that contain TG and to a lesser extent, 
cholesterol esters in the core.  These particles have apolipoprotein B on their surfaces that 
ensure the structural integrity of the lipoprotein particles, act as cofactors for enzymes 
involved in the metabolism of the lipoprotein particles, and act as ligands for receptors 
that process these particles32.   
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 Regulation of triglyceride levels can occur by alterations of free fatty acids 
available both from the diet and from adipose tissue stores.  At the small intestine, 
manipulation of the packaging of free fatty acids in the enterocyte can be performed. 
 Cholesterol and triglyceride metabolism can also be regulated transcriptionally.  
Transcriptional factors important in lipid metabolism include peroxisome proliferators-
activated receptors (PPAR) and sterol regulatory element binding proteins (SREBP)33.  
PPAR’s are important transcription factors that maintain lipid homeostasis by regulating 
fatty acid flux from peripheral tissues to the liver and the hepatic oxidation of fatty 
acids34.  PPARα is expressed in the liver, heart and skeletal muscle35,36.  Activation of 
PPARα down regulates hepatic apoC-III, upregulates lipoprotein lipase (LPL) expression 
and reduces VLDL secretion 37-39.  PPARγ expression upregulates LPL in adipocytes and 
enhances peripheral LPL-mediated lipolysis of triglycerides decreasing total circulating 
triglycerides35,38.  PPARδ expression reduces triglycerides and LDL-C while elevating 
HDL-C and enhancing cholesterol efflux40. 
 SREBPs are proteins that exist as three different isoforms, SREBP-1a, -1c, and -
241.  SREBP-1a and -1c are involved in the regulation of enzymes involved in fatty acid 
and triglyceride metabolism, including fatty acid synthase, acetyl-CoA carboxylase and 
lipoprotein lipase42,43.  Overexpression of SREBP-1a activates both cholesterol and fatty 
acid synthetic genes which results in an accumulation of TG and cholesteryl esters in an 
enlarged fatty liver42.  SREBP-1c is selective in activating fatty acid biosynthetic genes42.  
SREBP-2 is involved in transcriptional changes in cholesterol synthesis; HMG-CoA 
reductase, HMG-CoA synthase and the LDL receptor42,44.  
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1.2.3 Transport 
 
Figure 1.1 – A simplified view of cholesterol and triglyceride transport.  Apolipoprotein 
(apo)B is a protein component of chylomicrons (Cm), VLDL, LDL, intermediate density 
lipoproteins (IDL) and remains with these particles throughout their catabolism. A1, C3 
and A4 readily exchange between lipoproteins of different classes.  CETP = cholesterol 
ester transfer protein; CmR = chylomicron remnant particle; FFA = non-esterified fatty 
acids; LCAT = lecithin-cholesterol acyltransferase and * = ApoA1 (Diagram used with 
permission of Oxford University Press14|. 
 
 VLDL is a particle that is assembled in the liver and acts as a transporter for non-
dietary lipid formed from the catabolism of dietary carbohydrates, the recycling of 
cellular membranes and the esterification of free fatty acids derived from adipose tissue45-
48.  HDL particles which are secreted from the small intestine and liver return excess 
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cholesterol from peripheral tissues to the liver for excretion into the bile49.  These sources 
of cholesterol include macrophages/foam cells, plaques, peripheral tissues and the 
products of chylomicron remnant particles, IDL, and LDL50,51.  Small dense-LDL 
particles are the results of increased transfer of cholesteryl esters from HDL to 
intermediate lipoproteins and from LDL to VLDL.   
 When the particle is secreted in the plasma where it undergoes delipidation by 
capillary bound lipoprotein lipase, VLDL successively loses triglyceride fatty acids from 
the core, which are taken up by the peripheral cells and the liver.  VLDL particles are 
ultimately transformed into LDL particles that only contain cholesterol esters in their 
core.  These particles are either normally metabolized by LDL receptors to be taken up by 
peripheral tissues as a cholesterol donor or by hepatocytes.  They can also become 
transformed so that they are no longer recognized by the receptors.  This can include 
being metabolized into small dense LDL particles that may undergo phagocytotic uptake 
by macrophages that produce foam cells, and foster atherosclerotic plaque formation.   
 
1.2.4 Catabolism 
 Cholesterol 7α-hydroxylase catalyzes the conversion of cholesterol to bile acids 
in the liver and is the rate limiting step in cholesterol catabolism52.  Increased activity of 
this enzyme results in decreased total serum cholesterol levels53. 
 The LDL receptor is responsible for the clearance of LDL-C from blood in the 
liver54.  With increases in LDL receptor expression, there is an increased rate of LDL-C 
uptake from circulating cholesterol from LDL particles. 
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 LPL is an enzyme that is highly expressed in cardiac and skeletal muscle as well 
as adipose tissue.  Its action is to enhance VLDL receptor activity activating VLDL 
lipolysis and the hydrolysis of TG within the particle55.  This releases free fatty acids for 
use as energy or storage56.  
 
1.3 Animal Models of Hyperlipidemia 
 Both genetic and environmental manipulations have been carried out in rodents to 
establish a model system that best mimics hyperlipidemia in humans57-60.  Due to the 
variability in the causes of dyslipidemia, researchers have utilized both types of models.   
 Genetic models of hyperlipidemia often involve the genetic alteration of one gene, 
which often leads to changes in the expression of other genes and protein activity. Thus 
genetic models of hyperlipidemia can be complex systems to work with.  The genetically 
obese Zucker fatty rat arose from the cross-breeding between Sherman and Merck stock 
M rats57.  The “fa” gene for “fatty” was transmitted as a Mendelian recessive trait and 
this resulted in an obese rat strain57.  The animals are not only obese but also share the 
similarities of obese patients with insulin-resistance or Type 2 diabetes.  Yet this rat 
strain differs from humans in that Zucker rats have increased HDL-C to LDL-C ratios, 
which makes this species unsuitable for studies for CVD58.  Alterations to this state can 
be made by increasing the dietary intake of saturated fats and cholesterol58.   
 The leading genetic animal model for obesity is the spontaneously hypertensive 
obese rats that carry a nonsense mutation in the leptin receptor59.  These animals show 
multiple phenotypes including abdominal obesity, spontaneous hypertension, 
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hyperinsulinemia, and hyperlipidemia; features that closely resemble those of human 
metabolic syndrome X60. 
 In Western populations, the remarkable increase in the incidence of 
hyperlipidemia has been too sudden to be solely due to genetic factors.  Genetically 
independent methods involving alterations in dietary energy intake are effective and 
relevant for the study of hyperlipidemia61.  For studies involving a single lipid parameter 
(i.e. cholesterol or triglyceride), dietary manipulations to rodents are regularly used.   
Hypercholesterolemia in rodents is induced by supplementing cholesterol or 
saturated fats into laboratory rodent chow62.  There are different variations on the rodent 
chow but most include 1-4% cholesterol in the diet with additions of cholic acid and 
thiouracil to support induction of hyercholesterolemia62-65.  Others include coconut oil 
which is high in myristic, lauric and palmitic acids which have also shown to induce a 
hypercholesterolemic state in rats66.  Depending on the type of diet, hypercholesterolemia 
itself or other related disease states can be induced at the same time.  Supplementation of 
rats with a 1% cholesterol diet is able to induce hypercholesterolemia without causing 
changes in blood pressure meanwhile diets with 4% cholesterol causes hypertension67. 
Hypertriglyceridemia is most often induced by increasing concentrations of 
simple sugars, most often sucrose, glucose or fructose in the diet68-70.  Though some 
studies have utilized the administration of sucrose or glucose in the diet, the most 
common and effective additive is fructose68,70.  High sugar diets promote hepatic 
triglyceride synthesis through the lipolytic pathway, VLDL production, decreased 
catabolism of TG-rich lipoproteins and increase fatty acid synthesis by the liver71.   With 
dietary manipulations, more than one disease state may also be induced.  The most 
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common method for induction of hypertriglyceridemia is 60% fructose in rodent chow.  It 
not only induces hypertriglyceridemia but also insulin resistance in rodents 69,72.  In 
contrast, studies that utilize 10% fructose in water induce hypertriglyceridemia without 
insulin resistance68.  The differences within dietary manipulations are important for 
induction of certain dyslipidemic states while avoiding others.  
 Obesity is often achieved by feeding rodents high-calorie “cafeteria” type diets73-
77.  This method provides an attractive model for the study of obesity due to its simplicity 
and its resemblance to obesity in Western society.  Variations to this diet range from 
highly-purified diets, where a certain percentage of energy is consumed as fat (45-65%), 
to semi-purified diets that supplement calories with full fat sweetened condensed 
milk77,78, to diets where rodents are fed foods including cookies, liver pate, bacon and 
whole milk73,79,80.  The variations in content of the “cafeteria” diets complicate 
comparisons made between these studies. 
 Each rodent strain reacts to dietary manipulations in a different way too.  For 
example, the outbred male Sprague-Dawley shows a wide distribution in body weight 
gain when placed on an energy dense, high fat diet.  A subpopulation of male rats become 
very obese while others remain lean15.  On the other hand, weight gain in the male Wistar 
rat is more uniform within the strain71.  These physiological differences in diet induced 
hyperlipidemia models replicate the features in human obesity making rat models 
appealing tools for the investigation of human obesity15.  Much care must be taken to 
choose the appropriate model for the study of hyperlipidemia 
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1.4 Treatment of Hyperlipidemia 
1.4.1. Current Therapeutic Strategies 
 At this time, recommendations to reduce the risk of cardiovascular disease include 
lifestyle changes and the administration of pharmaceutical agents.  Increasingly however, 
patients are seeking alternatives to them and are looking towards natural alternatives.  
Depending on the risk level of a patient, one or combinations of different therapies may 
be utilized18,81.  Though there have been great advancements in pharmaceutical 
interventions in the past decades, many patients do not respond to the treatment and fail 
to meet the guidelines for serum lipid reductions8,82.  New strategies for lipid 
management are required to meet the needs of patients who do not respond to current 
therapies or are seeking alternatives. 
 
1.4.1.1 Lifestyle Changes 
 For individuals who have been diagnosed with hyperlipidemia, therapeutic 
lifestyle changes are important to reduce the risk of CVD.  This includes reducing the 
intake of saturated fats and cholesterol, enhancing consumption of LDL-C lowering foods 
and viscous soluble fibre, weight reduction and an increase in physical activity11,81.  It is 
recommended that individuals consume <7% of their total calories as saturated fats and 
<200 mg per day of cholesterol81.  Regular physical activity consisting of 30-60 minutes 
of endurance cardiovascular activities, 4-7 days a week is also recommended to attain and 
maintain a healthy body weight (BMI of 20-25)11.  These changes in lifestyle need to be 
consistent and permanent for the benefits to be reaped.  For individuals who are at high-
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risk for CVD, often lifestyle changes are not sufficient and other preventative measures 
must be taken. 
 
1.4.1.2 Pharmaceutical Agents 
 Currently various commercial pharmaceutical agents are available that function to 
decrease circulating LDL-C and TG and/or increase HDL-C.  These agents target both 
transcriptional and post-transcriptional points of regulation in cholesterol and TG 
homeostasis (Section 1.2).   
 Bile acids inhibit cholesterol absorption by decreasing micellular cholesterol 
solubilization within the gastrointestinal tract lumen. Several drugs function to modify 
lipid absorption from the gastrointestinal tract.  These drugs decrease biliary salt 
hydrophobicity thereby reducing the availability of cholesterol for absorption by the 
enterocytes25.  
Phytosterols, mainly campesterol and sitosterol, inhibit cholesterol absorption due 
to their chemical resemblance to cholesterol83.  Phytosterols inhibit intestinal cholesterol 
absorption by incorporating themselves into micelles in the intestinal lumen, displacing 
cholesterol84.  This leads to the precipitation of cholesterol with other nonplant sterols 
and eventually its excretion into the feces25.  Due to the decreased absorption of 
cholesterol, less cholesterol ester is available to be incorporated into chylomicrons within 
the enterocyte for export into the systemic circulation, resulting in lower circulating 
levels of cholesterol58.  However, phytosterols tend to reduce absorption of fat-soluble 
vitamins.  
 16
Ezetimbe is a new drug that is a potent and selective inhibitor of intestinal 
cholesterol absorption without inhibiting the passage of other fat soluble food 
nutrients26,28.  Ezetimbe undergoes rapid and extensive glucuronidation within the 
enterocyte during its first pass and is circulated enterohepatically repeatedly delivering 
the agent back to the site of action on the luminal surface of the enterocyte.  Ezetimbe is a 
more potent inhibitor when in its glucuronidated state25.  Although its exact mechanism is 
unknown, new research suggests ezetimbe may act by inhibiting the transporter 
Neimann-Pick C1-like protein (NPC1L1) or associated subunits and cofactors that 
facilitate the uptake of cholesterol into the enterocyte25. Inhibition of cholesterol 
absorption results in decreased cholesterol transfer to the liver, lowered hepatic 
cholesterol concentrations, upregulation of LDL receptors with concomitant increase in 
LDL-cholesterol uptake from the systemic circulation, and reduction in VLDL secretion 
and conversion to LDL-cholesterol in the blood stream28.   
A number of therapeutic agents act to alter lipid synthesis and catabolism. 
Nicotinic acid lowers the levels of all atherogenic lipoproteins and raises the 
concentration of the protective serum HDL-C and reduces elevated levels of 
chylomicrons85. Furthermore, nicotinic acid inhibits fatty acid mobilization from adipose 
tissue thereby reducing the supply of free fatty acids. This in turn decreases hepatic 
triglyceride synthesis, thus diminishing the triglyceride pool for VLDL production.  The 
reduction of VLDL particles subsequently leads to reductions of LDL-C85.  
 Statins are a class of drugs that inhibit cholesterol synthesis by inhibiting HMG-
CoA reductase, the rate limiting enzyme for cholesterol synthesis82.  By inhibiting HMG-
CoA reductase, statins inhibit endogenous production of cholesterol13.  When cells 
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require cholesterol, they must obtain it from circulating cholesterol.  To acquire adequate 
amounts of cholesterol for cellular functions, the cell must increase its concentration of 
LDL receptors on its surface.  This allows the cells to clear more LDL particles from 
plasma and thus reduce circulating LDL-C levels.   
 Fibrates modulate lipoprotein levels by 5 major mechanisms: 1) induction of 
lipoprotein lipolysis; 2) induction of hepatic fatty acid uptake and reduction of hepatic 
triglyceride production; 3) increased removal of LDL particles; 4) reduction in neutral 
lipid exchanges between VLDL and HDL decreasing plasma levels of triglyceride rich 
lipoproteins and increasing HDL-C production; and 5) stimulation of reverse cholesterol 
transport86.  The hypotriglyceridemic action of fibrates can be attributed to alterations in 
liver gene expression leading to a decreased production of VLDL particles, which renders 
them more susceptible to lipolysis and clearance from plasma.  The clearance from 
plasma is likely mediated by lipoprotein lipase and apolipoprotein C-III, two proteins that 
have antagonistic properties in triglyceride metabolism87.  Fibrates are also peroxisome 
proliferators-activated receptor alpha (PPARα) agonists.  PPARα is a transcription factor 
that when over expressed, increases the catabolism of fatty acids, which are important 
precursors for the synthesis of triglycerides. Its effects on HDL-C concentrations are also 
partly due to PPAR-mediated transcriptional regulation of apolipoproteins A-I, A-II and 
A-IV in the liver87.  Fibrates are most effective in decreasing TG and increasing HDL-C 
plasma levels to improve serum profiles.   
 Benfluorex is a hypotriglyceridemic drug whose metabolites inhibit de novo 
synthesis of fatty acids and triglyceride synthesis88.  Thiazolidinediones mediate their 
hypolipidemic effects through binding with and activation of PPARγ in adipose tissue.  
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The hypotriglyceridemic action of thiazolidinediones is mediated by a specific action on 
adipose tissue through the enhancement of lipoprotein lipase (LPL) expression causing 
enhanced triglyceride removal87. 
 
1.4.1.3 Natural Products 
 Increasing interest in alternative medicine and natural products both for the 
prevention and treatment of CVD has created a need for research into their mechanism of 
action. Several natural products are promoted for their lipid reducing characteristics.   
Cinnamate is a phenolic compound found in cinnamon bark and other plant materials.  
Oral consumption of cinnamon reduces serum glucose, TG, total cholesterol and LDL-
C89.  Cinnamate reduces cholesterol parameters by inhibiting hepatic HMG-CoA 
reductase activity89,90.  Sesamin, a lignan from the sesame seed, influences lipid synthesis 
but also regulates other enzymes important to cholesterol absorption (acyl-CoA: 
cholesterol acyltransferase (ACAT)), as well as the transcription factors PPARα and 
sterol regulatory element binding protein 1 (SREBP-1). Oral administration of sesamin 
resulted in a decrease in precursor SREBP-1 proteins and a larger decrease in mature 
forms of the protein.  Consequently, sesamin may modify the proteolytic process used to 
generate the mature form, causing down-regulation of gene expression of hepatic 
enzymes in fatty acid synthesis regulated by SREBP91.   
 Soy has been found to have hypolipidemic effects with reductions in plasma TG, 
and non-HDL lipoproteins with no effects on HDL-C with oral consumption in both 
humans and animals92,93.  Soy is a rich source of the isoflavones genistein and diadzein94.  
Soy protein and the isoflavones have been implicated as the biologically active 
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components within soy.  It has been found that with oral consumption of soy, there are 
significant reductions in fatty acid biosynthesis, the precursor for lipids94.  The 
mechanism of action is suggested to be a decrease in SREBP-1c, the principle regulator 
of fatty acid synthesis as well as a decrease in fatty acid synthase95.  
 Oral consumption of flaxseed has shown the potential to be therapeutically 
beneficial for the treatment or prevention of hyperlipidemia (see section 1.3.3).  
Identification of the component in flaxseed that exhibits its hypolipidemic effects is 
crucial to providing safe and effective administration guidelines. 
  
1.5 Flaxseed 
Flax (Linum usitatissumum) is a blue flowering crop that produces small, flat 
seeds that range in colour from golden yellow to a reddish brown.  The composition of 
biologically active components in flaxseed vary amongst varieties as well as growing 
conditions96.  On average, whole flaxseed contains 41% fat, 28% dietary fibre and 21% 
protein and minerals, vitamins and carbohydrates97.  The bioactive components of flax 
include the flaxseed oil (primarily α-linolenic acid), the mucilage and lignans.   
Speculated health benefits associated with flaxseed consumption include 
hypocholesterolemic effects98, estrogenic effects99, delay in the development of type II 
diabetes100, cancer chemoprevention101,102, antioxidant103, antithrombotic104, and anti-
atherogenic effects105.  
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1.5.1 Major Components of Flaxseed 
1.5.1.1 Flaxseed Oil 
Flaxseed oil is composed primarily of polyunsaturated fatty acids (73%) making it 
a low-saturated fat food97.  It is unique since it is the richest known source of omega-3 
fatty acids (α-linolenic acid/ALA).  The reported biological properties of ALA include 
effects on inflammatory responses106, neurological systems107 and the cardiovascular 
system.  It has been suggested that ALA may prevent atherosclerotic cardiovascular 
disease by decreasing inflammatory responses, inhibiting platelet aggregation and 
thrombosis, decreasing blood pressure as well as improving serum lipid levels and 
preventing cardiac arrhythmias108.  Studies of flaxseed oil and partially defatted flaxseed 
have suggested that ALA is not responsible for the hypolipidemic effects found with oral 
consumption of whole ground flaxseed meal109,110.  Partially defatted flaxseed was used 
to study the effects of flaxseed on serum cholesterol in the absence of high ALA 
intake109.  It was found that consumption of partially defatted flaxseed reduced total 
cholesterol, LDL-C, apo B and apo A-1109 while consumption of flaxseed oil did not 
show hypolipidemic effects110. 
 
1.5.1.2. Dietary Fibre 
 The fibre portion of flaxseed contains both insoluble and soluble fibre (mucilage), 
the latter is thought to be the biologically active portion109.  Mucilage has shown 
beneficial actions on the reduction of diabetes, coronary heart disease, prevention of 
colon and rectal cancer as well as the reductions in incidences of obesity111.  These 
effects are thought to be due to the nature of the fibre, which increases the viscosity of the 
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small intestine content, delaying digestion and absorption of carbohydrates and 
consequently reducing glycemic responses and improving glucose tolerance112,113.   
 Some research speculates that fibre can improve serum total cholesterol and LDL-
C, thus reducing the risk factors for CVD114.  The physiochemical properties of fibre, 
such as water-holding capacity, apparent solubility, binding affinity, degradability, 
particle size and alteration by processing are thought to attribute to its effects on serum 
lipids96,112.  It has been speculated that the reduction of LDL-C with the administration of 
flaxseed fibre are due to greater fecal loss of bile acids and increased primary bile acid 
synthesis98.  These effects are extrapolations from other sources of dietary fibre since 
extraction of the mucilage is difficult and often other biologically active components 
(lignans and cyanogenic glucosides) are not removed from the mucilage96,98. 
 
1.5.1.3. Lignans 
Plant lignans are a large class of phytochemicals that are formed by the fusion of 
two coniferyl alcohol residues and are structurally related to the lignins present in plant 
cell walls.  They are dimers of phenylpropane units, present in vacuoles and cell walls 
and are solubilized in organic solvents115.  They are found throughout the plant kingdom 
where they exist either as a glycoside or in their free form and are usually plant specific 
with flaxseed being the richest source of the lignan secoisolariciresinol diglucoside 
(SDG).  Flaxseed also has smaller quantities of matairesinol, isolariciresinol, lariciresinol, 
demethoxysecoisolariciresinol and pinoresinol116,117.  The level of SDG in flaxseed varies 
between 0.6 to 1.8/100g118,124 or 1-4% by weight119,120, 60-700 times greater than any 
other edible plant115,121 with the variability in components depending on the cultivar122,124, 
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the growing location and year123,124.  It has been suggested that the lignans within 
flaxseed are the beneficial components within flax125. 
 
1.5.2. Flaxseed Lignans 
1.5.2.1 Absorption 
 Flaxseed lignans are ingested as a polymer linked with hydroxyl-methyl-glutarate 
(HMG) with SDG as the principle lignan.  Upon reaching the stomach, the acidic 
environment hydrolyses the complex into its monomeric form.  The non-specific action 
of β-glucuronidases and β-glucosidases present in the intestinal lumen and secreted by 
the mucosal cells then cleaves the glucosidic groups on SDG to produce 
secoisolariciresinol121,126,127.  Once SDG has been converted to its aglycone SECO, the 
lignan becomes more hydrophobic and thus is able to traverse the intestinal wall and 
enter the blood stream.  SECO that is not absorbed in the small intestine continues into 
the large intestine where intestinal bacteria convert it to the mammalian lignans 
enterodiol (ED) and enterolactone (EL).  Demethylation and dehydroxylation of SECO 
results in ED which can then be oxidized into EL128.  It has been suggested that the 
bacteria responsible for the conversion are Peptostreptococcis sp. and Eubacterium sp129. 
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Figure 1.2 – Pathways for the conversion of SDG-HMG polymer to EL in in vivo 
systems.  SDG-HMG polymer is converted to SDG by the acidic environment of the 
stomach.  The glucoside groups are cleaved from SDG be β-glucuronidase to its aglycone 
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form secoisolariciresinol (SECO).  SECO can be converted to matairesinol (MAT), 
lariciresinol (LAR) and enterodiol (ED) by the bacterial microflora of the large intestine.  
LAR can also be formed in the liver by cytochrome P450 –mediated metabolism.  MAT, 
ED and LAR can all be converted to EL by intestinal microflora.  Pathways were 
revealed by using human fecal innoculum.121,128 
 
1.5.2.2 Metabolism 
 Once absorbed across the gastrointestinal mucosa, lignans are transported to the 
liver via the portal vein where they can undergo extensive conjugation followed by 
excretion into the bile127,130.  Upon return to the intestine they can be deconjugated to 
continue enterohepatic circulation131,132.  Lignans may also undergo extensive 
conjugation by the intestinal mucosal cells131 before entering the portal circulation. 
Mammalian lignans can also be acted upon by β-glucuronidase to convert it to its 
unconjugated form within the intestinal lumen132 to be excreted out of the body or be 
reconjugated to continue enterohepatic recirculation. 
Oxidative metabolism of SECO in rat liver microsomes gave rise to 4 different 
metabolites, but predominantly lariciresinol and isolariciresinol133.  SECO can also be 
converted into matairesinol, which when incubated with rat liver microsomes is able to 
produce 10 different metabolites.  Virtually no metabolites were generated when 
incubated with human liver microsomes suggesting that oxidative metabolism of 
matairesinol is mediated by a specific isoform only present in rat and not human liver133.  
In this same study, when SECO and matairesinol was administered in vivo to rats, no 
oxidative metabolites were detected in 24 hour urine and most of the administered dose 
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was found as ED and EL133.  This suggests oxidative metabolism is a minor elimination 
pathway for the lignans. 
EL and ED both have weak estrogenic activity.  It is unclear at this time whether 
the plant or mammalian lignans are the biologically active components of flaxseed.  
 
1.5.2.3 Pharmacokinetics of Lignans 
 It was found that the lignan SDG can be metabolized to produce mammalian 
lignans in vivo130.  Studies in both rats and humans found that total mammalian lignan 
levels increase linearly with dose with a plateau in serum levels being reached in rats at a 
dose of 5% flaxseed or 2.2µmol/d SDG130.  At 25g flaxseed per day in humans, there was 
no plateau reached130.  Plasma lignan concentrations peaked at 9 hours after initial 
consumption, maintained 24 hours after intake and did not return to baseline by 24 hours 
after flaxseed ingestion suggesting that flaxseed ingestion once a day is sufficient to 
maintain plasma concentrations130.  Regardless of previous exposure to SDG, more than 
50% of lignans were excreted in feces and 30% is present in the urine with low retention 
following 48 hours after administration130.  It was also found that blood clearance takes 
longer than 48 hours130.  Following administration, the tissues that had the largest 
concentration of lignan metabolites are involved in SDG metabolism (liver, intestine and 
kidneys)130.  Chronic exposure to SDG resulted in a delay in fecal lignan excretion and 
increased uptake of lignan metabolites by the liver and adipose tissues suggesting that 
there may be an increase in bacterial activity and hence more efficient absorption of 
lignans130. 
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 In vivo studies of single doses of SECO at 10mg/kg or 2.92 x 10-5 mol/kg body 
weight in female Wistar rats showed that the major compounds in urine are the 
mammalian lignans which were excreted in higher amounts than the dose of SECO 
given134.  This demonstrates that intestinal bacteria extensively convert SECO to 
mammalian lignans134.  Oxidative metabolites were not found in the urine suggesting that 
they do no play a significant role for in vivo systems134.  In a more recent study, it was 
found that ED, EL and SECO constituted the majority (75-80%) of urinary lignans 
detected in rats with acute or chronic treatment of SDG135.  A small amount of four other 
lignan metabolites were found in rats fed SDG but not identified135.  It was found in this 
study that chronic administration of SECO produced constant urinary SECO levels but 
with acute administration, urinary levels were significantly higher at 12 hours versus all 
other time points135.  Rats that have not been exposed to SDG required 24 hours to reach 
steady stat 135.  The proportion of ED, EL and SECO in 24 hour urine with chronic 
administration of SDG is 55, 10 and 13% respectively135. 
 
1.5.3 Hypolipidemic Effects 
Studies show flaxseed intake lowers cholesterol levels and possibly triglyceride 
levels in both human98,136-138 and animal model60,93,105,139,140 systems.  The possible 
synergistic action of different components within flax that may contribute to the 
hypocholesterolemic effects associated with flaxseed consumption remains unknown.  
Prior flaxseed research has focused on the estrogenic activity of the mammalian lignans, 
enterodiol (ED) and enterolactone (EL).  However, much controversy exists over the 
active component and the mechanism of action for flaxseed.  
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1.5.3.1 Human Studies 
 Studies have been performed in humans to evaluate the effects of flaxseed or its 
components on serum lipids.  Various clinical trials suggest that whole flaxseed meal is 
able to modestly reduce total cholesterol and LDL-C in hypercholesterolemic and 
normocholesterolemic patients without a significant effect on HDL-C or TG112.  In one 
study it was found that two weeks consumption of partially defatted flaxseed is effective 
in lowering LDL-C levels98,109 as well as reducing total cholesterol, apolipoprotein B and 
A-I with no significant changes in serum HDL.  Another study in healthy subjects 
showed that consumption of 50 g of flaxseed per day for 4 weeks resulted in significant 
reductions in LDL-C138.  While another study showed that flaxseed supplementation in 
the form of flaxseed bread or 15g ground flaxseed per day for 3 months resulted in 
significant reductions in serum total and LDL-C with no changes in HDL-C in 
hyperlipidemic subjects137.  A similar study with hypercholesterolemic subjects without 
diabetes or obesity fed partially defatted flaxseed showed similar results98.  These studies 
show that the effects of flaxseed in different forms in different model systems.  Though 
the data from these studies is not consistent, the main result of lowered LDL-C levels was 
found.  Furthermore, the data suggests that ALA is not responsible for the changes in 
lipid levels seen with flaxseed consumption.  In the study with partially defatted flaxseed, 
ALA levels were very low yet reductions in LDL-C were similar to that of whole ground 
flaxseed.    
Some researchers speculate that the modest changes in serum lipids are due to the 
fibre and lignans in flaxseed.  In one study, improved laxation in the participants was 
suggested to partly explain the decrease in LDL cholesterol by an increase in fecal 
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excretion of bile salts136.  These data suggests that the gum is likely an active ingredient 
in flaxseed, but also suggests that studies on isolate gum and lignan components need to 
be performed98.  Studies to evaluate the lipid effects of extracted flaxseed lignans in 
humans are now in progress.   
 
1.5.3.2 Animal Studies 
 Studies in animals have shown conflicting results with the administration of 
flaxseed.  In some studies, administration of flaxseed has been shown to cause significant 
reductions in LDL-C and TG with increased HDL-C levels while others have not seen the 
same results. 
 In Fisher 355 rats as well as both lean and obese spontaneously 
hypertensive/NIH-corpulent rat (SHR/N-cp), a 20% whole flaxseed meal beginning at 8-
10 weeks of age significantly decreased plasma total cholesterol and TG following 6 
months feeding60,93.  It also decreased liver steatosis, a condition often found in patients 
with hyperlipidemia93.  Meanwhile, in weanling female Sprague-Dawley rats fed 10% 
whole ground flaxseed and 6.2% partially defatted flaxseed for 56 days, no significant 
changes in total cholesterol were found and triglyceride levels were increased108.  This 
suggests that flaxseed may have a different effect depending on the animal model used.  
Furthermore, this stresses the importance of experimental design for animal studies of 
flaxseed. 
 Studies of purified SDG have been more consistent regardless of the animal 
model used.  In rabbits on a 1% cholesterol diet, flaxseed (7.5 g/kg) consumption for 8 
weeks led to lower cholesterol levels and an increased HDL-C:LDL-C ratio in a SDG 
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dependant manner105,140.  Another study found that oral administration of 40 mg/kg SDG 
for 4 weeks starting at 6 weeks of age was able to decrease the level of antioxidants and 
reactive oxygen species causing damage to pancreatic β-cells100.  It was also able to 
retard hyperglycemia and impaired glucose tolerance in the onset of diabetes100.  The 
study suggests that SDG may be the biologically active component in flax producing 
beneficial effects to the prevention/treatment of lipid related diseases.  
 
1.5.4 Toxicity 
The bioactive components of flaxseed may have potentially beneficial effects yet 
only a few studies have been reported in the literature regarding the potential the 
unfavorable consequences of ingesting concentrated or purified components of flaxseed.   
 The literature reports some concern that the consumption of large quantities of 
uncooked flaxseed could result in toxicity due to the cyanogenic content of 
flaxseed112,125.  The authors of one study suggest consumption of high doses of uncooked 
flaxseed meal may raise HCN levels above 50 mg of inorganic cyanide, which could be 
potentially toxic to adults112.  However, baking flaxseed removes this theoretical risk.   
 Other flaxseed components including the fibre have been thought to affect iron, 
zinc, calcium and phosphorus status, but studies have shown no significant health 
problems due to flaxseed consumption in humans108. 
 The phytoestrogenic activity of flaxseed lignans, particularly the mammalian 
lignans, has raised interest for their potential effects on the development of reproductive 
cancers, promotion of liver cancer and on pregnancy and developmental outcomes. In one 
study SDG administration to pregnant rats resulted in lower birth weights and 
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pronounced hormonal effects both in males and females141. Yet a more recent study 
showed no effects on the estrous cycle of female rats or pregnancy outcomes in rats fed 
flaxseed in their diet during and after pregnancy142.  Furthermore, flaxseed did not alter 
developmental parameters such as viability, fetal weight and size, bone ossification, 
anogenital distances and anogenital indices or behaviour after birth125.  Behavioral tests 
on developing rats indicate that flax is without effect125.  In these studies, different strains 
of rats were used suggesting that certain strains may be more resistant to the effects of 
flaxseed or SDG125,141,142.  
In addition, serum levels of alanine aminotransferase and γ-
glutamyltranspeptidase were not altered in rats suggesting that flax is not hepatotoxic125.  
In this study, there were no metabolic effects on glucose balance or metabolism in the 
animals125.  In a study with Chinese hamsters, the genotoxic potential of the aglycone 
form of SDG was evaluated.  The results did not suggest any changes in micronuclei or 
gene mutations in the cells of theses animals143.   
 The current data available regarding the safety of flaxseed consumption is 
insufficient to evaluate its potential toxicity when the lignan component is extracted and 
administered in a concentrated form.  Furthermore, populations such as the elderly or 
pregnant may be more susceptible to toxicity due changes in their physiology and thus 
must also be evaluated to determine the safety of purified lignans. 
 
1.6. Perspectives  
Studies in our laboratory indicate that flaxseed lignans contribute to the 
hypocholesterolemic effect observed with flaxseed consumption (unpublished data, M. 
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Tait M.Sc. Thesis). Whether flaxseed lignans influence triglyceride homeostasis remains 
controversial. Current hypolipidemic therapies do not adequately allow the majority of 
patients to attain their target lipid levels. Hence, new therapeutic agents with novel 
mechanisms of action may aid patients in reaching their lipid level goals. Understanding 
flaxseed lignans role and mechanism of action in lipid homeostasis is necessary to 
promote flaxseed or its purified lignans as potential therapeutic agents in the treatment of 
hyperlipidemia. A necessary adjunct to such studies includes investigations into the 
safety of flaxseed lignans and their pharmacokinetics. 
  
 32
2. Purpose of Project 
2.1 Rationale 
 Previous studies in our lab demonstrated favorable effects on serum and hepatic 
cholesterol parameters in diet-induced hypercholesterolemic rats with daily oral 
administration of purified flaxseed lignans.  The studies suggested that the lignans 
mediate a clinically relevant hypocholesterolemic effect, yet low sample sizes precluded 
statistically significant results, and previous studies failed to elucidate lignan mechanism 
of action.  Furthermore, published human clinical studies report possible flaxseed effects 
on serum triglyceride parameters, but the effects of flaxseed lignans on serum and hepatic 
lipids in hypertriglyceridemic and obese animal model systems had not yet been 
evaluated to corroborate these findings.  Finally, a complete pharmacokinetic evaluation 
of purified forms of flaxseed lignans has not been conducted and such information is 
critical to support the safety and efficacy of lignans as natural products. 
 
2.2 Hypothesis 
Flaxseed lignans reduce serum and hepatic lipids through alterations in the 
transcriptional regulation of enzymes and proteins important to lipid metabolism. 
 
2.3 Objectives 
2.3.1  Use rat models of dietary manipulation to assess the influence of the 
flaxseed lignan, secoisolariciresinol diglucoside, on hypertriglyceridemia, 
hypercholesterolemia and obesity and the mechanisms involved. 
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2.3.1.1 Analysis of serum and intrahepatic lipids following dietary 
manipulations and daily oral dosing of SDG. 
2.3.1.2 Assessment of SDG effects on hepatic and body weight and 
histopathological effects on hepatic lipid accumulation  
2.3.1.3 Analysis of alterations of mRNA expression of molecular targets 
involved in lipid metabolism.  
2.3.1.4 Determine the effects of SDG on hepatic, renal and immunological 
function through analysis of blood chemistry and hematological 
parameters. 
 
2.3.2  Provide a preliminary pharmacokinetic assessment of SECO 
2.3.2.1 Evaluate the distribution and elimination of SECO following an IV 
and oral bolus in rats. 
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3. Materials and Methods 
3.1 Food Intake with Daily Oral SDG Administration 
3.1.1 Animals 
  Female Wistar rats (n = 6) were obtained from Charles River Canada (St. 
Constant, Quebec) at a weight range between 150-200g (∼8 weeks).  Rats were housed 
individually with controlled temperature (22oC ± 2oC), and maintained on a 12 hour 
light:dark cycle (0700 to 1900 hours).  All rats were fed a standard laboratory rat chow 
and water was provided ad libitum.  The experimental protocol was approved by the 
University Committee on Animal Care and Supply (UCACS) in accordance with 
Canadian Council of Animal Care (CCAC) guidelines. 
3.1.2 Study design 
 Rats were randomized on the day of arrival into treatment and control groups. All 
rats were allowed a one-week acclimatization period to become accustomed to the 
handling and oral gavage procedures.  Each animal was weighed daily and food intake 
was measured every other day. Each animal was administered 0.2mL volume with the 
SDG concentration varying according to body weight (8.8 µmol/kg (equivalent to 6.06 
mg/kg) body weight dissolved in 0.9% sodium chloride) or vehicle (0.9% sodium 
chloride) by daily gavage for 4 weeks.  All doses were administered between 1-2 pm.  
Fasted (12 h) blood samples were collected at 4 weeks by cardiac puncture under 
isoflurane anesthesia for serum lipid analysis (see Section 3.1.3).  All blood samples were 
collected within a one-hour period between 6:30 am and 7:30 am.  The rats were 
euthanized by an overdose of isoflurane anesthesia and exsanguination. 
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3.1.3 Serum lipid analysis 
 Blood samples were allowed to clot for 30 minutes and serum was separated by 
centrifugation at 3,000 revolutions per minute (rpm) for 5 minutes in a Beckman TJ-6 
Centrifuge (rotor TH-4, Beckman Coulter Inc, Fullerton, CA) and transferred to sterile 
1.5mL centrifuge tubes.  Serum total cholesterol (TC), triglycerides (TG) and high 
density lipoprotein cholesterol (HDL-C) were determined by colorimetric analysis with 
commercial kits (Stanbio Laboratory, Boerne, TX) according to the manufacturer 
directions except for the following manipulations.  For total cholesterol 10µL of serum or 
cholesterol standard (200mg/dL) was added to 1mL of cholesterol reagent (Stanbio No. 
1010) and vortex-mixed immediately.  Following a 10 minute incubation at room 
temperature, the absorbance was measured at 500nm using an UV/Vis Spectrophotometer 
(#8453E Agilent Technologies, Palo Alto, CA) blanked to cholesterol reagent.  For 
triglyceride determination, the same method as that of total cholesterol analysis was used 
except a triglyceride standard replaced the cholesterol standard. Serum TC and TG were 
calculated with Equation 3.1. 
 200×−=
Abs
AbsAbs
ardandSt
Blank SerumUnknown
  desTriglyceri or lCholestero Total       (3.1) 
 Stanbio precipitating reagent (Stanbio No. 0599) was added to 100µL of serum, 
vortex-mixed and incubated at room temperature for 5 minutes.  Samples were then 
centrifuged (21,000 x g for 2 minutes) using a Micromax Thermo IEC centrifuge 
(Thermo IEC, Needham Heights, MA) to separate non-HDL-C.  The samples or standard 
was then added to 1mL of cholesterol reagent (Stanbio No. 1010) and, following a 10 
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minute incubation at room temperature, the absorbance was measured at 500nm using 
cholesterol reagent as a blank.  HDL-C was calculated using Equation 3.2. 
55×=−
Abs
Abs
Standard
Unknown
CHDL                 (3.2) 
The Friedewald method86 was used to calculate the LDL-C levels, which subtracts HDL-
C and very low-density lipoprotein cholesterol (VLDL-C) from TC with VLDL 
calculated as one-fifth the level of TG (Equation 3.3). 
 
5
TG - C-HDLTCC-LDL −=                 (3.3) 
The use of the Friedewald method for LDL-C calculation had been previously validated 
in our laboratory (Unpublished data, M. Tait M.Sc. Thesis). 
3.1.4 Statistical analysis 
Daily food intake and rate of weight gain analysis was carried out using GraphPad 
Prism 4.0 (GraphPad Software, San Diego, CA).  All results were expressed as mean ± 
SEM.  Differences between mean values for the control and the treatment group were 
tested using an unpaired two-tailed student’s t-test with a significance level set at α < 
0.05. 
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3.2 Dose-Response Effects of SDG on Rats Fed 10% Fructose in Water: 
Female Wistar Rat Model 
3.2.1 Animals 
Female Wistar rats (n = 8) were obtained from Charles River Canada at a weight 
range between 100 and 125g (∼ 6 weeks).  Animals were housed in groups of two or 
three with controlled temperature (22oC ± 2oC), and were maintained on a 12 hour 
light:dark cycle (0700 to 1900 hours).  The experimental protocol was approved by 
UCACS. 
3.2.2 Study design 
 On the date of arrival, rats were randomly assigned to either control or 10% 
fructose in water treatment groups and acclimatized to handling and oral gavage 
procedures for one week.  Animals consumed standard rat laboratory chow and tap water 
during the acclimatization period ad libitum.  After the acclimatization period, 10% 
fructose in water replaced the regular tap water in those groups requiring fructose 
feeding. Eight animals were in each group with 4 treatment groups: 1) Tap water; 2) 10% 
Fructose in tap water; 3) 10% Fructose in tap water with 4.4 µmol SDG/kg (equivalent to 
3.03 mg/kg) body weight; and 4) 10% Fructose in tap water with 8.8 µmol SDG/kg 
(equivalent to 6.06 mg/kg) body weight.   
 Rats were weighed daily and SDG or vehicle (0.9% sodium chloride) (total 
volume = 0.2mL) was administered by daily oral gavage at the same time of day (1-2 
pm).  Blood samples from fasted animals were collected under isoflurane anesthesia at 0 
(pre-dose baseline) and 2 weeks via saphenous venepuncture and via cardiac puncture at 
 38
4 weeks for serum lipid analysis.  All blood samples were collected within a two-hour 
period beginning at 6 am.  At 4 weeks, rats were euthanized by an overdose of isoflurane 
anesthesia and exsanguination.  Liver, heart and retroperitoneal adipose tissue were 
rapidly excised, weighed, and sectioned for total RNA analysis, histological analysis 
and/or lipid analysis.  Samples for RNA analysis were stored in RNAlaterTM solution 
(Sigma, Saint Louis, MI) at -20oC.  Portions of liver were flash-frozen in liquid nitrogen 
and stored at -80oC until analysis or fixed in 10% formalin solution for routine histology.  
Retroperitoneal adipose and cardiac tissue were rapidly excised and flash frozen in liquid 
nitrogen and stored at -80oC. 
3.2.3 Serum lipid analysis 
  Blood samples were allowed to clot for 30 minutes and serum was separated by 
centrifugation and transferred to sterilized 1.5mL centrifuge tubes.  Serum triglycerides 
(TG), total cholesterol (TC) and HDL-C were determined by colorometric analysis with 
commercial kits (Stanbio).  The kits were used as specified by the manufacturer except as 
indicated in section 3.1.3. 
3.2.4 Statistical analysis 
 Graph Pad Prism 4.0 was used for statistical analysis.  All results are expressed as 
mean ± SEM.  Comparisons between treatment groups were made using a one-way 
analysis of variance (ANOVA) with a Bonferroni’s post hoc test with a p-value < 0.05.   
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3.3 Dose-Response Effects of SDG on Rats fed 10% Fructose in Water: 
Male Sprague-Dawley Rat Model 
3.3.1 Animals 
  Male Sprague-Dawley rats were obtained from Charles River Canada at a weight 
range of 100 to 125g.  Animals were housed individually with controlled temperature 
(22oC ± o2C), and were maintained on a 12 hour light:dark cycle (0700 to 1900 hours).  
The experimental protocol was approved by UCACS  
3.3.2 Study Design 
  On the date of arrival, rats were randomly assigned to either control or 10% 
fructose in water and acclimatized to handling and oral gavage procedures for one week. 
Animals consumed standard rat laboratory chow and tap water during the acclimatization 
period ad libitum.  After the acclimatization period, 10% fructose in water replaced the 
regular tap water in those groups requiring fructose feeding. Ten animals were in each 
group with 4 treatment groups: 1) Tap water; 2) 10% Fructose in tap water; 3) 10% 
Fructose in tap water with 4.4 µmol SDG/kg body weight; and 4) 10% Fructose in tap 
water with 8.8 µmol SDG/kg body weight.   
  Rats were weighed daily and SDG or vehicle (0.9% sodium chloride) was 
administered by daily oral gavage within a 2 hour period.  Fasted blood samples were 
collected under isoflurane anesthesia at 0 (pre-dose baseline) weeks via saphenous 
venepuncture, and at 2 weeks via cardiac puncture for serum lipid analysis.  All blood 
samples were collected within a two hour period beginning at 6 am.  At 2 weeks, rats 
were euthanized by an overdose of isoflurane anesthesia and exsanguination.  Liver, heart 
and retroperitoneal adipose tissue were rapidly excised, weighed, and sectioned for total 
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RNA analysis, microsomal preparation, histological analysis and lipid analysis.  Samples 
for RNA analysis were stored in RNAlaterTM solution at -20oC.  Portions of liver were 
flash-frozen in liquid nitrogen and stored in -80oC and fixed in 10% formalin solution for 
routine histology.  Retroperitoneal adipose and cardiac tissue were flash-frozen in liquid 
nitrogen and stored at -80oC. 
3.3.3 Serum lipid analysis 
  Blood samples were allowed to clot for 30 minutes and serum was separated by 
centrifugation and transferred to sterilized 1.5mL centrifuge tubes.  Serum triglycerides 
(TG), non-esterified fatty acids (NEFA) and phospholipids (PL) were determined by 
colorometric analysis with commercial kits (Stanbio Laboratory, Boerne, TX and Wako 
Chemicals USA Inc, Richmond, VA) immediately following serum collection.  The kits 
were used as specified by the manufacturer. 
3.3.4 Intrahepatic lipid analysis 
 All liver samples for intrahepatic lipid analysis had been flash-frozen in liquid 
nitrogen and stored at -80oC until analysis.  At the time of analysis, 50 mg of liver was 
weighed out and placed into a 15mL homogenization tube with 4mL of 2:1 
chloroform:methanol solution.  Following homogenization with a Polytron homogenizer 
and filtration, the filtrate was then extracted by the method of Folch et al.144.  Briefly, 
sulfuric acid was added the filtrate and the lower phase was washed with pure solvents 
(Chloroform:Methanol:Water at 3:48:47) and the upper phase removed.  Following the 
wash steps, methanol was added to combine the lower phase and the remaining 
interphase.  The sample was then dried under nitrogen.  Triton X-100 was used to 
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resolubilize the sample in deionized water at 37oC for analysis.  Hepatic triglycerides 
were determined by colorimetric analysis (Stanbio).   
3.3.5 Statistical Analysis 
 Graph Pad Prism 4.0 was used for statistical analysis.  All results are expressed as 
mean ± SEM.  Comparisons between treatment groups were made using a one-way 
analysis of variance (ANOVA) with a Bonferroni’s post hoc test with a p-value < 0.05.   
3.3.6 Analysis of Molecular Targets 
3.3.6.1 RNA isolation 
Total RNA was isolated using RNAEasy Midi, RNA isolation kits (Qiagen Inc, 
Mississauga, ON) as specified by the manufacturer’s protocol.  100mg of liver stored in 
RNAlater was used and homogenized in RLT buffer provided by the kit.  Following 
centrifugation at 4500 x g, the supernatant was removed and added to a clean 
polypropylene tube with an equal volume of 50% ethanol.  The sample was shaken 
vigorously for 15 seconds and then applied to the Midi column.  Following several 
washes with buffers provided in the kit, total RNA was eluted from the Midi column with 
500µL RNase-free water.  An UV/Vis spectrophotometer (Agilent) was used to assess 
RNA purity by measuring the ratio of absorbance at 260:280nm.  Quantification of RNA 
was performed by measuring the absorbance at 260nm (Equation 3.4).    
factorDilution /40][ 260 ××= AmlgRNA µ               (3.4) 
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3.3.6.2 Real-time RT-PCR 
  Primer sequences (Table 3.1) for molecular targets important in triglyceride 
metabolism were designed using Primer3 software (www.broad.mit.edu/cgi-
bin/primer/primer3).  Gene sequences were obtained from NCBI’s Genebank. 
 
Table 3.1 – Accession numbers, primer sequences and amplicon size for real time RT-
PCR of transcription factors regulating triglyceride homeostasis. 
Gene Accession No. Left Primer Right Primer Amplicon Size (bp) 
SREBP-1c L16995 gtgtcagcttgtggcactgg atgcctcggctatgtgaagg 236 
PPAR-α M88592 agggctatcccaggctttgc gatgtcgcagaatggcttcc 189 
 
  Using QuantiTect SYBR Green Master Mix (Qiagen Inc, Mississauga, ON), 
quantitative real-time RT-PCR was performed on hepatic total RNA (30ng) with final 
primer concentrations of 1 µM in a reaction volume of 25µL.  Using a SmartCycler® 
(Cepheid, Sunnyvale, CA) (Table 3.2), validation and optimization for an annealing 
temperature that resulted in the highest primer efficiency (E) was performed (Equation 
3.5) using non treated Sprague-Dawley male livers as positive control tissue. An optimal  
 
E
CSlope T log
1)( −=                  (3.5) 
annealing temperature produces a single specific melt peak, which is not identified in a 
negative control (i.e. a blank sample which does not contain RNA). RT-PCR products 
were verified by polyacrylamide gel electrophoresis for a single band at the specified 
amplicon size and correlated to the product melt peak.  Efficiency was calculated from 
the slope of a 3 point standard curve using serial dilutions of control RNA and annealing 
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temperatures were altered to ensure that the efficiency of the target and the internal 
control gene (β-actin) was approximately equal and slopes fell within a range of -2.8 to -
3.5. The reactions were quantified following determination of the threshold cycle (CT), 
the amplification cycle when PCR products are first detected above baseline 
fluorescence.  Fluorescence was measured after the elongation period. A non-template 
negative control was incorporated into all analysis runs. 
 
Table 3.2 – SmartCycler general RT-PCR protocol 
Step Time Temperature (oC) 
Reverse Transcription 30 min 50 
PCR Initial activation 15 min 95 
Denaturation 15 sec 94 
Annealing 30 sec Varied with primer 
Extension 30 sec 72 
 
  The samples were normalized to total RNA added to each reaction.  
Quantification of targets in the unknown samples was determined by interpolation from a 
five point standard curve produced from serial dilutions of the appropriate control tissue 
(i.e. male Sprague-Dawley liver).  The results are reported in arbitrary units as well as 
percentage change with the control groups set as 100%. 
3.3.7 Statistical analysis 
  Statistical analysis was performed using Graph Pad Prism 4.0.  All results are 
expressed as mean ± SEM.  Comparison between each of the treatment groups were 
performed using an ANOVA with a Bonferronni’s post hoc test with a p-value of < 0.05. 
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3.4 Effects of SDG on Female Wistar Rats Fed 1% Cholesterol Diet or 
Energy Dense Diet 
3.4.1 Animals 
  Female Wistar rats were obtained from Charles River Canada at a weight range of 
100 to 125g.  Animals were housed 3 or 4 per cage with controlled temperature (22oC ± 
o2C), and were maintained on a 12 hour light:dark cycle (0700 to 1900 hours).  The 
experimental protocol was approved by UCACS.  
3.4.2 Study Design 
  On the date of arrival, rats were randomly assigned to standard laboratory rat 
chow diet, 1% cholesterol supplemented diet (Diet #9396 TestDiet, Richmond, IN) or 
obesity diet (Diet #58V8 TestDiet, Richmond, IN), and acclimatized to handling and oral 
gavage procedures for one week.  Animals consumed food and water ad libitum.  Ten 
animals were assigned to each group with 6 treatment groups: 1) Standard laboratory rat 
chow; 2) Standard laboratory rat chow with daily oral administrations of 4.4 µmol 
SDG/kg body weight; 3) 1% Cholesterol supplemented diet; 4) 1% Cholesterol 
supplemented diet with daily oral administrations of 4.4 µmol SDG/kg body weight; 5) 
Obesity diet; and 6) Obesity diet with daily oral administrations of 4.4 µmol SDG/kg 
body weight.  Rats were weighed daily and SDG or vehicle (0.9% sodium chloride) was 
administered by daily oral gavage within a 2 hour period.  Fasted blood samples were 
collected under isoflurane anesthesia at 0 (pre-dose baseline) and 2 weeks via saphenous 
venepuncture, and via cardiac puncture at 4 weeks for serum lipid analysis.  All blood 
samples were collected within a two hour period beginning at 6 am.  At 4 weeks, rats 
were euthanized by an overdose of isoflurane anesthesia and exsanguination.  Liver, 
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heart, retroperitoneal and visceral adipose and intestinal tissue were rapidly excised, 
weighed and sectioned for total RNA analysis, microsome preparation, histological 
analysis and lipid analysis.  Samples for RNA analysis were stored in RNAlaterTM 
solution at -20oC.  Portions of liver were flash-frozen in liquid nitrogen and stored in -
80oC or fixed in 10% formalin solution for routine histology.  Retroperitoneal adipose 
and cardiac tissue were flash-frozen in liquid nitrogen and stored in -80oC. 
3.4.3 Serum lipid analysis 
  Blood samples were allowed to clot for 30 minutes and serum was separated by 
centrifugation (3,000 rpm, 5 minutes) and transferred to a sterile 1.5mL centrifuge tube.  
Serum total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol 
(HDL-C) and low density lipoprotein cholesterol (LDL-C) were determined by 
colorimetric analysis with commercial kits (Stanbio and Wako).  The kits were used as 
specified by the manufacturer.  
3.4.4 Intrahepatic Lipid Analysis 
  Extraction of intrahepatic cholesterol was performed by the same method 
specified in Section 3.3.4.  Colorimetric analysis with commercial kits (Stanbio and 
Wako) was performed as specified by the manufacture.   
3.4.5 Safety Evaluation 
  Blood was collected for hematology and blood chemistry for evaluation of SDG’s 
effect on the renal, hepatic, and immune systems.  Complete blood chemistry and 
hematology were performed by Royal University Hospital, Saskatoon, SK. 
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3.4.6 Statistical Analysis 
  Graph Pad Prism 4.0 was used for statistical analysis.  All results are expressed as 
mean ± SEM.  Comparisons between treatment groups were made using a one-way 
analysis of variance (ANOVA) with a Bonferroni’s post hoc test with a p-value < 0.05.   
 
3.5 Pharmacokinetic Pilot Study with IV Bolus and Oral Administration of 
SECO 
3.5.1 Animals 
 Two female Wistar rats were obtained from Charles River Canada weighing 
between 200-250g.  The rats were housed individually with controlled temperature (22 
+/- 2°C), and maintained on a 12 hour light:dark cycle (0700 to 1900 hours).  The 
experimental protocol was approved by UCACS. 
3.5.2 Study Design  
 One day prior to IV bolus administration, the rats underwent surgery for the 
implantation of vascular cannulas (Silastic tubing, I.D. x O.D. (0.63 x 1.19 mm)). The 
rats were anesthetized with isoflurane gas.  The right jugular vein and left femoral vein 
were exposed and cannulated.  With oral administration, only the right jugular vein was 
cannulated.  The cannulas were passed under the skin and fixed near the base of the neck.  
A heparin lock was instilled into the cannula until lignan administration and blood 
sampling. 
  Rats were fasted overnight before lignan administration. On the test day, the rats 
received intravenously or orally a single bolus of SECO dissolved in molecular grade 
polyethylene glycol 300 (Sigma-Aldrich), Tween 80 (Sigma-Aldrich) benzyl alcohol 
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(Sigma-Aldrich) and ethanol (Sigma-Aldrich) (65:8:3:24, v/v/v/v) at a dose of 10 mg/kg 
(2.92 x10-5 mol/kg).  Intravenous injection was given over a 30 second period via the 
femoral vein cannula.  For oral administration, an oral gavage tube (20g, 2 in) with an 
attached 1mL syringe was used to administer the oral SECO dose.  Blood samples (250 
µL) were drawn into a syringe via the jugular vein-cannula at 0, 2, 5, 10, 20, 30, 60, 90, 
120, 150, 180, 210, 240, 360 and 480 minutes after drug administration.  After each 
blood sample ~250 µL saline was reinstilled into the rats. Blood samples were allowed to 
clot for 30 minutes and serum was transferred to a clean 1.5 mL centrifuge tube for 
storage at –20°C until time of analysis.  
3.5.3 HPLC analysis of serum 
SECO was kindly donated by Agriculture and AgriFood Canada and resorcinol 
was purchased from Spectrum (New Brunswick, NJ).  HPLC grade methanol, diethyl 
ether and acetonitrile (ACN) were purchased from EMD (Durham, NC) and HPLC grade 
triflouroacetic acid (TFA) was purchased from Sigma-Aldrich (Saint Louis, MI). 
The analyses were carried out on a Waters System (Waters Corporation, Milford, 
MA), which included a 717plus Autosampler, 600 Controller, 600 Pump and a 2996 
Waters Photodiode Array Detector.  The maximal absorbance for SECO and resorcinol 
occurred at 280 nm.  Waters Millenium Software (Waters Corporation, Milford, MA) 
was used for data acquisition and analysis. 
Lignans were separated with gradient elution.  The mobile phase consisted of (A) 
0.05% TFA in H2O and (B) 0.05% TFA in ACN.  The total flow rate was 1.0 mL/min 
with a gradient profile presented in Table 3.3.  The analytical column was a Nucleosil C18 
(Supelco Inc., Bellefonte, PA) 250mm x 4.6mm, 5µm particles.  The column was 
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maintained at room temperature. The total run time was 60 minutes and the injection 
volume was 100µL.  The retention times of SECO and resorcinol were 31.2 and 11.2 min 
respectively.   
 
Table 3.3 – HPLC gradient profile for the analysis of SECO and internal standard, 
resorcinol. 
Time (min) % A % B Curve 
0 95 5 6 
2 95 5 6 
5 90 10 6 
12 80 20 6 
20 80 20 6 
30 65 35 6 
33 50 50 6 
40 5 95 6 
48 5 95 6 
50 95 5 6 
55 95 5 6 
60 95 5 11 
 
3.5.4 Sample Pretreatment 
Serum samples (100µL) were thawed at room temperature and 100 µL of 5 
mg/mL resorcinol was added to all samples.  The samples were extracted using liquid-
liquid extraction with diethyl ether.  Briefly, 1 mL of diethyl ether was added to the 
sample and vortex-mixed for 5 minutes.  The samples were centrifuged for 10 min at 
3,000 rpm and the organic phase transferred to a clean labeled glass test tube.  This was 
repeated with 2 more volumes of 2.5 mL of diethyl ether145.  The organic layers were 
combined and dried under a stream of nitrogen.  The samples were dissolved in 250 µl of 
50mM Na2HPO4 for improved peak resolution and injected onto the HPLC system.  
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4. Results 
4.1 Food Intake Study 
 Our laboratory previously demonstrated significant differences in the rate of 
weight gain in rats treated daily with SDG and fed a 1% cholesterol diet (unpublished 
data, M. Tait, M.Sc. Thesis).  This present study was performed to determine if the 
changes in the rate of weight gain with SDG administration was due to lignan-induced 
alterations in food consumption.  A 4 week daily administration of SDG to female Wistar 
rats (150-200g) fed a standard laboratory chow resulted in no significant differences in 
final body weight, absolute weight gain, rate of weight gain or daily food intake as 
compared to control (Table 4.1).  Furthermore, no significant modifications in total 
cholesterol, HDL-C, TG or LDL-C as calculated by the Friedewald Equation were 
observed (Figure 4.1). 
 
Table 4.1 - Food intake and body weight parameters following 4 weeks of daily oral 
SDG administration.  Female Wistar rats (n=6) were fed standard rodent diet and dosed 
with 0.0 or 8.8 µmol SDG/kg body weight daily by oral gavage.  Body weight was 
measured daily and food intake every other day. Results are expressed as mean ± SEM. 
*P <0.05.  
Parameter 0 µmol/kg 8.8 µmol/kg 
Final body weight (g) 278 ± 8.0 275 ± 6.0 
Weight gain (g) 64.0 ± 6.0 61.0 ± 4.0 
Rate of weight gain (g/d) 2.28 ± 0.12 2.27 ± 0.11 
Daily food intake (g) 20.5 ± 0.20 19.9 ± 0.28 
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Figure 4.1 - Serum lipid analysis of female Wistar rats (n=6) fed standard rodent diet. 
Rats were randomly assigned to 0.0 or 8.8 µmol SDG/kg body weight administered by 
daily oral gavage for four weeks. Serum lipid levels were assessed with diagnostic kits 
following blood collection via cardiac puncture under light isoflurane anesthesia. Results 
are expressed as mean ± SEM. *P<0.05.  
 
4.2 Dose-response effects of SDG on rats fed 10% fructose in water: Female 
Wistar rat model 
 Current literature surrounding the effects of flaxseed has been ambiguous with 
regard to its effects on serum triglycerides.  To provide more direct evidence for flaxseed 
effects on serum and hepatic triglycerides, investigation of SDG mediated effects on a 
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hypertriglyceridemic rat model was undertaken.  Daily administration of SDG for four 
weeks did not modify final body weight, absolute weight gain or the rate of weight gain 
in female Wistar rats fed 10% fructose in water (designed to induce hypertriglyceridemia) 
(Table 4.2). 
 
Table 4.2 – Final body weight, absolute weight gain and rate of weight gain following 4 
weeks of SDG oral administration.  Female Wistar rats (n=8; 100-125) were fed standard 
rodent diet with or without (control) 10% fructose in water and dosed with 0.0, 4.4, or 8.8 
µmol SDG/kg body weight.  Results are expressed as mean ± SEM. *P <0.05. 
Parameter No Fructose 0 µmol/kg 
Fructose 
0 µmol/kg 
Fructose  
4.4 µmol/kg 
Fructose  
8.8 µmol/kg 
Final body weight (g) 241 ± 5.0 254 ± 5.0 252 ± 7.0 248 ± 6.0 
Weight gain (g) 67.0 ± 9.2 76.8 ± 3.0 79.7 ± 3.3 81.4 ± 1.5 
Rate of weight gain (g/d) 2.45 ± 0.10 2.98 ± 0.12 2.95 ± 0.13 2.70 ± 0.11 
 
 Evaluation of serum lipid parameters at baseline, 2 weeks and 4 weeks showed 
that 10% fructose in water failed to induce hypertriglyceridemia in female Wistar rats 
following 4 weeks with the dietary manipulation (Figure 4.2). 
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Figure 4.2 – Mean (± SEM) serum triglycerides at baseline, 2 weeks and 4 weeks.  
Female Wistar rats (n=8) were fed 0% or 10% fructose in water and dosed with 0.0, 4.4, 
or 8.8 µmol SDG/kg body weight. *P<0.05. 
 
4.3 Dose-response effects of SDG on rats fed 10% fructose in water: Male 
Sprague-Dawley rat model 
 Treatment of 10% fructose in water for the induction of hypertriglyceridemia in 
male Sprague-Dawley rats is used extensively in literature.  Our lab used this model to 
evaluate the effects of SDG in a hypertriglyceridemic rat model system.  Following 2 
weeks of fructose feeding, no significant differences were observed in final body weight, 
absolute weight gain, rate of weight gain, liver weight, heart weight or retroperitoneal fat 
weight with daily administration of SDG at 0, 4.4 or 8.8 µmol/kg body weight (Table 
4.3). 
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Table 4.3 – Final body weight, absolute weight gain, rate of weight gain, liver weight, 
heart weight and retroperitoneal fat weight following 2 weeks of daily oral SDG 
administration.  Male Sprague-Dawley rats (n=10) were fed standard rodent diet with 0 or 
10% fructose in water and dosed with 0.0, 4.4, or 8.8 µmol SDG/kg body weight.  
Results are expressed as mean ± SEM. *P <0.05. 
Parameter 
No Fructose 
0 µmol/kg 
Fructose   
0 µmol/kg 
Fructose  
4.4 µmol/kg 
Fructose  
8.8 µmol/kg 
Final body weight (g) 281 ± 6 306 ± 8 285 ± 6 296 ± 8 
Weight gain (g) 91.0 ± 13 100 ± 38 83.0 ± 32 106 ± 20 
Rate of weight gain (g/d) 6.90 ± 0.08 8.40 ± 0.10 6.90 ± 0.10 7.90 ± 0.10 
Heart Weight (g) 1.24 ± 0.05 1.27 ±  0.04 1.17 ± 0.04 1.21 ± 0.05 
Liver Weight (g) 8.80 ± 0.30 16.1 ± 0.83 15.2 ± 0.65 14.7 ± 0.76 
Retroperitoneal Adipose 
Tissue Weight (g) 2.30 ± 0.20 4.50 ± 0.60 3.60 ± 0.40 3.60 ± 0.30 
  
Analysis of serum triglycerides showed that 2 weeks of treatment with 10% 
fructose in water induced hypertriglyceridemia in male Sprague-Dawley rats.  However, 
no statistically significant changes in serum triglycerides, phospholipids, non-esterified 
fatty acids or intrahepatic triglycerides were observed with the administration of SDG at 
4.4 or 8.8 µmol/kg SDG relative to control.   
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Figure 4.3 – Mean (± SEM) serum triglycerides, non-esterified fatty acids (NEFA) and 
phospholipids and intrahepatic triglycerides following 2 weeks of SDG administration by 
daily oral gavage.  Male Sprague-Dawley rats (n=10) were fed 0 or 10% fructose in water 
and dosed with 0.0, 4.4 or 8.8 µmol SDG/kg body weight. Blood was collected via 
cardiac puncture under isoflurane anesthesia at 2 weeks. Serum and intrahepatic lipid 
parameters were measured by colorimetric analysis.  Results are expressed as mean ± 
SEM. 
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 Using real time RT-PCR, analysis of mRNA expression levels of hepatic SREBP-
1c and PPAR-α showed no statistically significant changes with administration of SDG 
at 4.4 or 8.8 µmol/kg SDG relative to control (Table 4.4).   
 
Table 4.4 - mRNA expression levels of hepatic PPAR-α and SREBP-1c for male 
Sprague-Dawley rats (n=10) fed 0 or 10% fructose in water. Rats were administered 0, 
4.4, or 8.8 µmol SDG/kg body weight by daily oral gavage for a period of two weeks. 
Results are expressed as arbitrary unit (*) mean ± SEM and as a percent of control. 
Parameter 
No Fructose  
0 µmol/kg 
Fructose   
0 µmol/kg 
Fructose  
4.4 µmol/kg 
Fructose   
8.8 µmol/kg 
PPAR-α 100 % 
54.8* ± 4.7 
66.1 % 
36.2* ± 4.6 
89.8 % 
49.2* ± 8.2 
86.6 % 
47.5* ± 9.7 
SREBP-1c 100 % 
2.14* ± 0.36 
1640 % 
35.3* ± 9.3 
1490 % 
31.8* ± 6.2 
1010 % 
21.7* ± 5.3 
 
 
4.4 Effects of SDG on female Wistar rats fed 1% cholesterol diet. 
 Although previous studies in our laboratory showed marked changes in serum 
cholesterol parameters with flaxseed lignan administration, statistically significant 
differences in the previous studies were not observed likely due to insufficient sample 
size. In attempts to produce statistically significant results, we repeated the evaluation of 
the affects of SDG in female Wistar rats (100-125) fed 1% cholesterol diet for five weeks 
using the same study design and protocol as the previous study, but with a larger sample 
size.  Evaluation of final body weight, absolute weight gain and rate of weight gain 
showed no significant difference with administration of SDG to rats fed either a basal diet 
or diet with 1% cholesterol (Table 4.5).  The observed liver, heart and retroperitoneal 
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weights were also not modified with daily dosing of SDG at 4.4 µmol/kg SDG relative to 
control. 
 
Table 4.5 – Final body weight, absolute weight gain, rate of weight gain, liver weight, 
heart weight and retroperitoneal fat weight following 4 weeks of daily oral SDG 
administration.  Female Wistar rats (n=10) were fed standard rodent or 1% cholesterol 
diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  Results are expressed as mean 
± SEM. *P <0.05. 
Parameter Basal 0 µmol/kg 
Basal 
4.4 µmol/kg
1% Chol 
0 µmol/kg 
1% Chol 
4.4 µmol/kg 
Final body weight (g) 239 ± 22 235 ± 17 236 ± 17 236 ± 24 
Weight gain (g) 93 ± 4 96 ± 3 92 ± 5 90 ± 5 
Rate of weight gain (g/d) 3.2 ± 0.085 3.2 ± 0.090 3.1 ± 0.87 3.0 ± 0.090 
Liver Weight (g) 6.8 ± 0.25 6.9 ± 0.14 7.9 ± 0.23 8.5 ± 0.45 
Heart Weight (g) 0.8 ± 0.028 0.8 ± 0.017 0.9 ± 0.030 0.8 ± 0.033 
Retroperitoneal Adipose 
Tissue Weight (g) 1.4 ± 0.11 1.2 ± 0.19 1.3 ± 0.14 1.1 ± 0.11 
   
Following 5 weeks of feeding 1% cholesterol in the diet, total cholesterol levels 
were not induced to a hypercholesterolemic level as that of previous studies (unpublished 
data, M. Tait, M.Sc. Thesis).  Serum total cholesterol levels were not significantly altered 
with daily oral administration of SDG in rats on either basal diet or 1% cholesterol at 
baseline, 2 weeks or 4 weeks (Figure 4.4).  
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Figure 4.4 – Mean (± SEM) serum total cholesterol at baseline, 2 weeks and 4 weeks 
with SDG administered by daily oral gavage.  Female Wistar rats (n=10) were fed a 
standard diet or 1% cholesterol diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  
Baseline measurements were taken following 1 week acclimatization period to a 1% 
cholesterol diet.  Results are expressed as mean ± SEM. 
 
 Serum HDL-C levels decreased in cholesterol fed rats in comparison to rats fed a 
basal diet (Figure 4.5).  The data show a decrease in serum HDL-C with administration of 
a 1% cholesterol diet in comparison to the basal diet with 45% and 38% difference 
between groups at 2 and 4 weeks, respectively.  No significant alterations in serum HDL-
C were found with daily oral administration of SDG in animals fed basal or 1% 
cholesterol diets.  
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Figure 4.5 - Mean serum HDL-C levels at baseline, 2 weeks and 4 weeks with SDG 
administration daily by oral gavage.  Female Wistar rats (n=10) were fed a 1% 
cholesterol diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  Baseline 
measurements were taken following 1 week acclimatization period to a 1% cholesterol 
diet.  Results are expressed as mean ± SEM. 
 
 Feeding 1% cholesterol to rats caused significant changes in serum LDL-C levels 
(Figure 4.6).  Comparison of basal control and 1% cholesterol diet groups showed a 
218%, 661% and 538% increase of LDL-C levels at baseline, 2 week and 4 week data 
collection.  However, daily oral administration of SDG did not significantly alter serum 
LDL-C levels. 
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Figure 4.6 - Mean serum LDL-C levels at baseline, 2 weeks and 4 weeks with SDG 
administration daily by oral gavage.  Female Wistar rats (n=10) were fed a 1% 
cholesterol diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  Baseline 
measurements were taken following 1 week acclimatization period to a 1% cholesterol 
diet.  Results are expressed as mean ± SEM. 
 
 Feeding 1% cholesterol diet to female Wistar rats did not change serum 
triglycerides (Figure 4.7).  Daily oral administration of SDG did not alter serum 
triglycerides in animals fed basal or 1% cholesterol diets. 
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Figure 4.7 - Mean serum TG levels at baseline, 2 weeks and 4 weeks with SDG 
administration daily by oral gavage.  Female Wistar rats (n=10) were fed a 1% 
cholesterol diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  Baseline 
measurements were taken following 1 week acclimatization period to a 1% cholesterol 
diet.  Results are expressed as mean ± SEM. 
 
4.5 Effects of SDG in female Wistar rats fed Energy Dense Diet 
 Female Wistar rats (100-125g) fed obesity diet for five weeks demonstrated no 
significant changes in final body weight, absolute weight gain, rate of weight gain, liver 
weight, heart weight and retroperitoneal adipose tissue weight with oral administration of 
SDG (Table 4.6). 
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Table 4.6 - Final body weight, absolute weight gain, rate of weight gain, liver weight, 
heart weight and retroperitoneal fat weight following 4 weeks of daily oral SDG 
administration.  Female Wistar rats (n=10) were fed standard rodent or obesity diet and 
dosed with 0.0 µmol or 4.4 µmol SDG/kg body weight.  Results are expressed as mean ± 
SEM. *P <0.05. 
Parameter 
Basal  
0 µmol/kg 
Basal  
4.4 µmol/kg 
Obs 
0 µmol/kg 
Obs  
 4.4 µmol/kg
Final body weight (g) 239 ± 22 235 ± 17 250 ± 19 247 ± 20 
Weight gain (g) 93 ± 4 96 ± 3 107 ± 4 102 ± 5 
Rate of weight gain (g/d) 3.2 ± 0.085 3.2 ± 0.090 3.8 ± 0.074 3.6 ± 0.078 
Liver Weight (g) 6.8 ± 0.25 6.9 ± 0.14 7.4 ± 0.21 7.6 ± 0.21 
Heart Weight (g) 0.8 ± 0.028 0.8 ± 0.017 0.9 ± 0.029 0.9 ± 0.054 
Retroperitoneal Adipose 
Tissue Weight (g) 1.4 ± 0.11 1.2 ± 0.19 2.8 ± 0.18 2.5 ± 0.38 
 
At baseline, 2 and 4 weeks, an obesity diet did not produce lipid levels that are 
considered dyslipidemic (Figure 4.8, 4.9, 4.10 and 4.11).  Total cholesterol levels were 
not induced to a hypercholesterolemic state at baseline, 2 and 4 week measurements.  
Administration of SDG did not significantly alter total cholesterol levels in groups fed 
basal or obesity diets.   
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Figure 4.8 – Mean (± SEM) serum total cholesterol at baseline, 2 weeks and 4 weeks 
with SDG administered by daily oral gavage.  Female Wistar rats (n=10) were fed a 
standard diet or an obesity diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  
Baseline measurements were taken following 1 week acclimatization period to an obesity 
diet.  Results are expressed as mean ± SEM. 
 
 HDL-C levels were not altered by feeding an obesity diet to female Wistar rats 
(Figure 4.9).  Daily oral administration did not cause significant changes in HDL-C levels 
at 2 or 4 week measurements. 
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Figure 4.9 - Mean serum HDL-C at baseline, 2 weeks and 4 weeks with SDG 
administration daily by oral gavage.  Female Wistar rats (10/group) were fed an obesity 
diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  Baseline measurements were 
taken following 1 week acclimatization period to an obesity diet.  Results are expressed 
as mean ± SEM. 
 
 Serum LDL-C levels were not significantly altered at the baseline, 2 week or 4 
week measurements with feeding of obesity diet (Figure 4.10).  Daily oral administration 
of SDG did not significantly decrease serum LDL-C levels. 
 64
Baseline 2 weeks 4 weeks
0
10
20
30
40
Basal Control
Basal & 4.4mmol/kg
Obs Control
Obs 4.4 mmol/kg
LD
L-
C
 (m
g/
dl
)
 
Figure 4.10 - Mean serum LDL-C at baseline, 2 weeks and 4 weeks with SDG 
administration daily by oral gavage.  Female Wistar rats (10/group) were fed a high fat 
diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  Baseline measurements were 
taken following 1 week acclimatization period to an obesity diet.  Results are expressed 
as mean ± SEM. 
 
 The obesity diet was not able to induce hypertriglyceridemia in juvenile female 
Wistar rats (Figure 4.11).  Administration of SDG did not significantly alter triglyceride 
levels in basal or obesity diet groups. 
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Figure 4.11 – Mean (± SEM) serum triglycerides at baseline, 2 weeks and 4 weeks with 
SDG administered by daily oral gavage.  Female Wistar rats (n=10) were fed a standard 
diet or an obesity diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  Baseline 
measurements were taken following 1 week acclimatization period to an obesity diet.  
Results are expressed as mean ± SEM. 
 
4.6  Effects of Chronic Oral Daily Administration (4 weeks) of SDG (4.4 
µmol/kg) on Organ Gross Morphology and Blood Chemistry and 
Hematological Parameters 
 Blood chemistry and hematology showed that daily oral administration of SDG 
for four weeks to animals fed a basal diet did not cause significant alterations in any of 
the clinical parameters (Table 4.7).  A statistically significant change in red blood cell 
distribution width (RDW) was observed at P < 0.05, but this is not considered clinically 
relevant. 
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Table 4.7 – Blood chemistry and hematology parameters in rats following 4 weeks of 
daily SDG administration by oral gavage.  Female Wistar rats (n=10) were dosed with 0.0 
or 4.4 µmol SDG/kg body weight.  Results are expressed as mean ± SD.   
Parameter Control       Mean               SD 
4.4 µmol/kg  
     Mean                SD 
WBC (109/L) 5.12 2.47 4.39 1.72 
RBC (1012/L) 7.05 0.346 6.86 0.238 
Hemoglobin (g/L) 149 8.14 146 5.14 
Hematocrit (L/L) 0.426 0.024 0.412 0.014 
MCV (fl) 60.5 1.00 60.2 1.71 
MCH (pg) 21.2 0.411 21.3 0.699 
MCHC (g/L) 350 3.74 353 3.23 
RDW % 11.8 0.335 12.4 0.652 
Platelet (109/L) 1080 237 1110 122 
MPV (fl) 6.04 0.368 6.07 0.245 
Neutrophil (109/L) 0.178 0.126 0.374 0.275 
Lymphocyte (109/L) 4.73 2.28 3.86 1.68 
Monocyte (109/L) 0.000 0.000 0.020 0.063 
Eosinophil (109/L) 0.050 0.070 0.050 0.070 
Basophil (109/L) 0.160 0.254 0.090 0.218 
Na (mmol/L) 139 2.29 140 2.17 
K (mmol/L) 4.17 0.654 3.76 0.653 
Cl (mmol/L) 105 1.70 104 2.90 
CO2 (mmol/L) 23.2 2.30 24.1 2.18 
Urea (mmol/L) 6.45 1.56 5.84 0.950 
Creatinine (µmol/L) 34.3 5.67 36.7 5.19 
Anion Gap (mmol/L) 11.8 1.13 11.7 0.948 
ALP (U/L) 110 29.6 117 35.6 
ALT (U/L) 30.2 5.33 33.7 6.32 
AST (U/L) 78.0 26.2 78.7 22.7 
CK (U/L) 216 256 268 305 
Glucose Random (mmol/L) 7.48 0.726 7.61 1.41 
Bilirubin (µmol/L) 8.90 1.59 7.90 1.10 
Calcium (mmol/L) 2.51 0.090 2.50 0.101 
Phosphate (mmol/L) 1.95 0.366 1.90 0.144 
Protein Total (g/L) 58.4 3.02 56.6 3.89 
Albumin (g/L) 19.2 2.00 18.6 1.78 
Osmolality (mmol/kg) 295 4.00 296 3.31 
The standard parameters measured are; white blood cell (WBC) counts, red blood 
cell (RBC) counts, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), 
 67
RDW, platelet count, mean platelet volume (MPV), neutrophil count, lymphocyte count, 
monocyte count, eosinophil count, basophil count, sodium (Na), potassium (K), chloride 
(Cl), carbon dioxide (CO2), urea, creatinine, anion gap, alkaline phosphatase (ALP), 
amino alanine transferase (ALT), aspartate amino transferase (AST), creatine kinase 
(CK), random glucose, bilirubin, calcium, phosphate, total protein, albumin and 
osmolality. 
Table 4.8 – Final body weight, absolute weight gain, rate of weight gain, and organ 
weights following 4 weeks of daily oral SDG administration.  Female rats (n=10) were 
fed standard rodent diet and dosed with 0.0 or 4.4 µmol SDG/kg body weight.  Results 
are expressed as mean ± SD. *P <0.05. 
Parameter Control Mean            SD 
4.4 µmol/kg SDG 
Mean               SD 
Final body weight (g) 239 22.0 235 17.0 
Weight gain (g) 93 4.0 96 3.0 
Rate of weight gain (g/d) 3.2 0.0085 3.2 0.0090 
Liver (g) 6.82 0.79 6.98 0.43 
Heart (g) 0.81 0.09 0.84 0.05 
Retroperitoneal Fat (g)  1.4 0.34 1.9 0.46 
Thymus (g) 0.5 0.06 0.5 0.07 
Lung (g) 1.2 0.15 1.2 0.10 
Spleen (g) 0.6 0.06 0.6 0.07 
Kidney – Left (g) 0.8 0.08 0.8 0.06 
Kidney – Right (g) 0.8 0.08 0.8 0.06 
Adrenal (g) 0.08 0.01 0.07 0.01 
Gross morphological changes to organs and in body condition were not observed 
with SDG administration to rats fed a basal diet.  Organ weights, as a gross measure of 
toxicity, were not found to be significantly different (Table 4.8).   
4.7 Pharmacokinetic Pilot Study with IV Bolus and Oral Administration of 
SECO 
 68
  A pilot study on the pharmacokinetics of SECO in female Wistar rats provided 
preliminary information on serum pharmacokinetics of SECO. Following an IV bolus of 
10 mg/kg SECO, serum levels of SECO were detected at 2, 5, 10, 15, 20 and 30 minutes 
following the dose by HPLC (Figure 4.12).  The peak height ratio versus time curve 
(Figure 4.12) suggests SECO exhibits two-compartment characteristics with a 
distribution half-life of approximately 26 seconds and an elimination half-life of 5 
minutes following an IV bolus.   
 An oral bolus of 10 mg/kg was also performed and serum samples were collected at 
specified intervals up to 8 hours. Following extraction, SECO was not detectable by 
HPLC in any of the samples.  
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Figure 4.12 - Log peak height ratio (chromatographic peak height of SECO/internal 
standard) of SECO following a 10 mg/kg body weight IV bolus dose to one female 
Wistar rat (6 weeks of age). 
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Discussion 
5.1 Food Intake Study  
 In our laboratory, we previously demonstrated that rats fed a 1% cholesterol diet 
and dosed daily by oral gavage with the flaxseed lignan, secoisolariciresinol diglucoside 
(SDG), showed a slower rate of weight gain in comparison to control rats fed 1% 
cholesterol diet.  To rule out the possibility that the slower rate of weight gain can be 
explained by SDG acting as an appetite suppressant, I compared absolute food intake 
between animals dosed daily by oral gavage either with vehicle or SDG while consuming 
a regular laboratory rat chow.  The results indicate no significant difference in daily food 
intake and rate of weight gain with administration of SDG at 8.8µmol/kg body weight 
relative to control.  This is consistent with several studies reported in the literature. For 
example, by 88 days of age female and male offspring whose mothers were fed regular 
laboratory rat chow supplemented with 10% ground flaxseed during the late gestation and 
lactation, and who were then fed the same supplemented diet upon weaning, showed no 
statistically significant changes in body weight gain as compared to non flaxseed 
supplemented offspring.125 Furthermore, New Zealand rabbits daily fed 7.5 g flaxseed per 
kg body weight140 or 15 mg (2.18 x 10-5moles) SDG per kg body weight118, also 
demonstrated no significant changes in body weight gain.   In a human study, women of 
normal body weight who consumed 40g of flaxseed per day for 12 months did not 
demonstrate changes in total body weight or BMI146. Furthermore, a study with 
hyperlipidemic subjects of normal body weight found that 50g partially defatted flaxseed 
per day did not alter body weight following 3 weeks treatment98. My study in 
combination with both human and animal studies using dietary flaxseed supplementation 
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suggest that neither flaxseed nor its lignan, SDG, acts as appetite suppressants or alters 
weight gain when administered daily with a well-balanced diet and to individuals of 
normal weight. However, SDG or flaxseed supplementation may have a protective effect 
against body weight gain following consumption of diets rich in cholesterol. Further 
investigations are required to explore this possible protective function of flaxseed or its 
purified lignans on body weight gain with hyperlipidemic diets. 
 
5.2 Dose-Response Effects of Secoisolariciresinol Diglucoside on Serum 
and Hepatic Triglyceride Levels 
5.2.1 Development of an Animal Model of Hypertriglyceridemia 
 In previous studies in our lab, we used female Wistar rats to investigate the 
hypocholesterolemic effects of SDG and its aglycone, SECO.  To maintain consistency 
with these previous studies, I planned studies to investigate the effects of SDG on 
triglyceride homeostasis in female Wistar rats.  I also chose to use a dietary model of 
hypertriglyceridemia, as previous studies in our lab had used dietary manipulations to 
induce hyperlipidemic states. 
 The literature reports various models of hypertriglyceridemia, including both 
genetic and dietary manipulated models68-70,93,147.  Genetic models of 
hypertriglyceridemia are often models of general hyperlipidemia, where all lipid levels 
are raised and complications such as hypertension also exist.  The spontaneously 
hypertensive NIH-corpulent (SHR/N-cp) rat with dyslipidemia is the most often used 
genetic model for the analysis of serum triglyceride levels93.  This animal model is used 
for the study of obesity and type-II diabetes mellitus, but it also exhibits insulin 
 71
resistance, glucose intolerance, hyperinsulinemia, hypercholesterolemia, 
hypertriglyceridemia and hypertension148.  Fisher 344 rats are a commonly used rat strain 
for studies of nutritional influences on growth and age-related processes,149,150 yet this 
strain exhibits normal serum lipid parameters.  The Zucker fatty/obese rat is also used for 
studies of hypertriglyceridemia, but it has the complications of type-II diabetes and 
obesity in conjunction with hyperlipidemia58.  These genetic models mimic human 
metabolic states that are a result of a genetic predisposition. However, the presence of 
complicating pathologies makes it difficult to assess the effects of a compound solely on 
hyperlipidemia.   
Dietary manipulations provide the ability to mimic the general diet of Western 
society where the increasing rates of hyperlipidemia are a result of the types and amounts 
of food consumed. Hypertriglyceridemia can be induced by the consumption of diets high 
in simple sugars, particularly fructose68.  Fructose is introduced into either the regular 
laboratory chow or the water supply of animals, with 66% and 10% fructose in each food 
source, respectively.  However, the addition of 66% fructose in rodent laboratory chow 
induces high blood pressure and insulin resistance in addition to 
hypertriglyceridemia69,151. Since I wished to determine SDG effects on 
hypertriglyceridemia solely, I utilized the 10% fructose in water model68.  Though this 
model is not used as frequently as the former model, it enables one to research the effects 
of a compound simply on triglyceride metabolism and, thus, is a valuable model for the 
study of hypertriglyceridemia. 
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5.2.2 Female Wistar Rats Fed 10% Fructose in Water  
 We conducted a study to determine the effects of SDG on hypertriglyceridemia in 
female Wistar rats using a 10% fructose in water model.  Following 4 weeks 
administration of fructose, the animals were not induced to a hypertriglyceridemic state.  
We attempted this method of induction since it has been found that in male Wistar rats, 
10% fructose in water for 21 days was sufficient to induce a hypertriglyceridemic state,68 
and we presumed that this method of induction would provide a hypertriglyceridemic 
model in females of the same strain. 
 Furthermore, in this study, a single water bottle containing 10% fructose in the 
water was the only water source for the rats. As well, the animals were housed in groups 
of 2 or 3 to maintain consistency with studies reported in the literature and to satisfy the 
humane treatment of the animals (rats are social animals and prefer group housing over 
individual housing).  During this study, I observed that a hierarchy among the rats existed 
within a cage, and competition for access to the one water source meant that the most 
dominant rat consumed the most fructose water.  Prior to the study, we did not take into 
consideration the behavior of animals housed in a group and, thus, this hierarchy within 
the cage may have contributed to our inability to induce a hypertriglyceridemic state. 
Funding constraints precluded any attempts to modify the experimental design and 
incorporate individual housing of female Wistar rats to assess whether this simple 
experimental design change may lead to an induction of a hypertriglyceridemic state in 
this gender and strain. Rather, a decision was made to use a well-established rat model of 
hypertriglyceridemia reported in the literature: the male Sprague-Dawley rat fed 10% 
fructose in water daily for two weeks.  
 73
5.2.3 Male Sprague-Dawley Rats Fed 10% Fructose in Water 
Due to our inability to induce hypertriglyceridemia in female Wistar rats, we 
altered our study design to use male Sprague-Dawley rats.  We used this strain and 
gender as they are most often used in fructose feeding studies69,72,147,151.  With this model 
we were effectively able to induce the animals to a hypertriglyceridemic state following 2 
weeks of daily 10% fructose in water feeding.  Since a distinct hierarchy within group 
caged animals was observed in the previous study, in the present study each animal was 
housed individually, which provided unobstructed access to the 10% fructose solution.  
Though it would have been interesting to determine the single or multiple factors 
that contributed to the success of this study in comparison to the previous study, we 
achieved our goal to provide an animal model of hypertriglyceridemia that allowed us to 
assess the affects of SDG on triglyceride metabolism. 
 
5.2.4 Effects of Secoisolariciresinol Diglucoside in a Rat Model of 
Hypertriglyceridemia 
 Male Sprague-Dawley rats fed 10% fructose in water for two weeks and dosed 
daily with vehicle by oral administration showed significant increases in serum lipid 
parameters relative to control (non-fructose fed rats). In this study, it was found that the 
transcription factors SREBP-1c and PPAR-α were significantly altered with fructose 
feeding.  A diet rich in carbohydrates stimulates lipogenesis in both the liver and adipose 
tissue which leads to increased plasma triglyceride levels152.  With fructose feeding, there 
was a significant increase in the level of expression of SREBP-1c.  It has been found that 
in mice that over express SREBP-1c in the liver, there is a build-up of hepatic 
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triglycerides and it has been suggested that SREBP-1c activates genes connected with 
lipogenesis153.  The expression levels of PPAR-α were significantly decreased with 
fructose feeding.  PPAR-α activation causes increased hepatic fatty acid uptake, increases 
conversion of fatty acids to acyl-CoA and increases β-oxidation of fatty acids154.  This 
decreases the availability of fatty acids for triglyceride synthesis.  Consequently, our 
findings suggest that decreased activity of PPAR-α would be related to increased 
triglyceride production, which we found as increases in plasma triglyceride levels.  
In this study, we found marked increases in liver weight with fructose feeding.  
The changes in liver weight in conjunction with the transcriptional changes found suggest 
that the fructose feeding stimulated lipogenesis in the liver as is the case with diets rich in 
carbohydrates152.  However, daily SDG administration at either dosing level caused no 
significant changes in serum triglycerides, phospholipids, NEFA and intrahepatic 
triglycerides relative to vehicle control fructose-fed rats.  In support of these findings, 
mRNA expression levels of hepatic SREBP-1c or PPAR-α showed no statistically 
significant differences with administration of SDG at 4.4 or 8.8 µmol/kg relative to 
fructose-fed vehicle controls.  Furthermore, body and organ weights were not statistically 
significant with administration of SDG in comparison to the fructose control group. 
 In other studies of hypertriglyceridemia, 20% flaxseed meal fed for 6 months to 
male Fisher 344 (F344) rats and both male lean and obese spontaneously 
hypertensive/NIH-corpulent (SHR/-cp) rats with dyslipidemia showed significant 
decreases in plasma triglycerides in all strains of rats60,93.  In a study using female Zucker 
rats, administration of 40 mg SDG per kilogram body weight did not influence serum 
triglyceride levels100.  A study of New Zealand rabbits supplemented daily with 7.5 g 
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flaxseed/kg on a 1% cholesterol diet showed a significant increase in triglyceride levels 
as a result of feeding flaxseed following 4 and 8 weeks administration in comparison to 
rabbits fed only a 1% cholesterol diet140.  In other similar studies using New Zealand 
rabbits, however no significant changes in serum triglyceride levels at 4 and 8 weeks 
were found with supplementation of 15 or 40 mg/kg SDG to animals on basal, 0.5% or 
1% cholesterol diet, respectively118,155.  In a human study of hypercholesterolemic female 
subjects, no significant changes were observed in the serum triglyceride levels following 
a diet that consisted of 40 g crushed flaxseed per day for 2 months99.  The results of our 
study and those of these reported studies indicate a lack of consensus of the effects of 
flaxseed or its purified lignans on serum triglyceride levels.  Many factors may contribute 
to these inconsistencies with oral consumption of flaxseed or its purified lignan and those  
may include the species and strain of animal, the age of the animals on which the studies 
were performed, the duration of flaxseed or lignan administration, as well as the type of 
flaxseed or flaxseed component that was fed.  From my study, I can conclude that in a 
10% fructose in water model in male Sprague Dawley animals who began daily oral 
consumption of SDG at 6 weeks of age, no significant changes were found in serum 
triglycerides following 2 weeks dosing at 4.4 µmol/kg or 8.8 µmol/kg (equivalent to 3.03 
mg/kg and 6.06 mg/kg). Whether SDG truly affects triglyceride homeostasis or not will 
require further investigations to explore potential strain and gender effects, and different 
genetic and/or dietary models of hypertriglyceridemia.  Given the conflicting information 
in the literature, my study does not definitively rule out the possibility that flaxseed 
lignans may affect triglyceride homeostasis.  A possibility exists that SDG affects 
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triglyceride metabolism in diet-induced hypertriglyceridemia via an alternative 
mechanism than that resulting from fructose feeding.  
Interestingly, a structural analogue of SECO (the aglycone form of SDG), 
masoprocol (nordihydroguiaretic acid or NDGA), significantly decreased serum 
triglyceride levels following twice daily oral administration at 80 mg/kg in male Sprague-
Dawley rats fed a 60% fructose diet for induction of hypertriglyceridemia151.  This study 
with a close structural analogue of SDG offers intriguing evidence for a possible effect of 
SDG on triglyceride homeostasis, but the results of my present study are in direct conflict 
with the NDGA study and do not directly support a role for SDG in hypertriglyceridemia.  
Two principal differences exist in the study design of the masoprocol experiment and my 
own research, namely the dietary manipulation method used to induce 
hypertriglyceridemia and the age at which the animals began the study.  In the 
masoprocol study, the animals weighed between 175 and 199 g at the initiation of the 
experiments. In my study, animals started at a weight between 100 and 125 g.  A 
comparison of these experiments highlights the importance of study design with respect 
to the age of animals used as well as the method for induction of hypertriglyceridemia. 
These observations also indicate the necessity for further investigations that compare 
species, strain, age, gender and method of dietary manipulation to induce hyperlipidemic 
states, to yield interesting metabolomic insights and possible insights into flaxseed lignan 
mechanisms of action. 
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5.3 Importance of Consideration of Species, Strain, Gender and Age in the 
Development of Dietary Manipulation Models of Hyperlipidemia 
 Animal models are used in research to provide detailed information on the effects 
of exogenous compounds on a biological system.  Dietary manipulations in rodent 
species are effective models to explore and mimic the nutritional activities in humans as 
well as interventions for disease states.  In Western societies, the incidences of CVD 
continue to rapidly increase and it remains a leading cause of death in Canada.  
Contributing factors to CVD include hypercholesterolemia, hypertriglyceridemia and 
obesity, all physiological alterations that can be due to changes in diet.  Dietary 
manipulations to rodents have proven effective to induce these disease states in animals 
that are not already genetically predisposed.  Consequently, introduction of high lipid or 
high carbohydrate rodent diets are often used to replicate the phenomenon found in 
Western societies.  The percentage of components within each diet, duration of treatment, 
model species and age are necessary to consider when performing an in vivo study.   
 Diets high in cholesterol bring about hypercholesterolemic serum levels with 
concentrations in cholesterol ranging from 1-4% in rodent diets63,65,67.  The cholesterol 
content of the diet is important, though, as higher cholesterol levels not only induce 
hypercholesterolemia but hypertension as well.  For the purpose of our study, we used a 
1% cholesterol diet to determine the effects of SDG on hypercholesterolemic animals, 
since this composition induces cholesterol without the concomitant development of 
hypertension.   
 In previous studies in our lab, a 1% cholesterol diet induced a significant 
hypercholesterolemic state in female Wistar rats following 5 weeks of feeding. 
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Furthermore, daily oral administration of SDG and SECO for four weeks to these 
hypercholesterolemic female Wistars produced marked dose-dependent trends with 
respect to SDG and SECO’s cholesterol lowering effects, but these trends were not 
statistically significant. Unfortunately, the hypothesis explaining the mechanism involved 
in flaxseed lignan-mediated reduction in serum and hepatic cholesterol parameters was 
not found in that previous study. Hence, in my thesis research, I repeated the study to 
determine if these trends were reproducible and to pursue an alternative hypothesis with 
regard to flaxseed lignans’ mechanism of action.  In my study, I repeated the study design 
except for the age of the animal. At the time I ordered the animals, the supplier (Charles 
River) did not have sufficient animals available in the age group requested.  I had to 
resort to a younger animal and on average the female Wistar rats used in my study were 
50 g smaller and two weeks younger.  To my surprise, hypercholesterolemia was not 
induced in my rats yet there was a significant increase in LDL-C and a significant 
decrease in HDL-C.  Since identical methods of induction were used, it suggests that the 
age of the animal is critical for induction of hyperlipidemic states with respect to dietary 
manipulations and that with longer treatment changes in total cholesterol may have been 
observed.  In this case, my study suggests that animals of a younger age are able to 
accommodate the increased cholesterol provided in the diet resulting in total cholesterol 
levels within normal range.  It also suggests that the mechanisms responsible for the 
control LDL-C and HDL-C levels are more sensitive to the increased cholesterol intake.  
Though longer treatment with a 1% cholesterol diet may have induced a 
hypercholesterolemic state, our study was terminated as planned and we were not able to 
pursue the alternative hypothesis on SDG’s effects on a hypercholesterolemic system. 
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Previous studies in our lab showed a significant decrease in rate of body weight 
gain in animals fed a 1% cholesterol diet and dosed daily orally with SDG. This suggests 
a possible protective effect of SDG against body weight gain following consumption of 
hyperlipidemic diets. Furthermore, my study with hypertriglyceridemic male Sprague-
Dawley rats did not definitively rule out a role for SDG in hypertriglyceridemia. Given 
these observations, I wished to evaluate the effects of SDG in a model system that 
concomitantly expressed both elevated serum cholesterol and triglyceride levels, and a 
model system that produced hypertriglyceridemia via dietary manipulation by a 
mechanism different from fructose feeding. Obesity is a pathological condition 
characterized by both elevated serum and triglyceride levels59.  A variety of diets exist to 
induce obesity in rats ranging from purified high fat rodent laboratory chow to diets 
consisting of “cafeteria” type foods including cookies, French fries and pizza71,73. 
Purified diets are often used when consistency of caloric consumption in the animals is 
required whereas a cafeteria type diet provides a model that closely mimics the eating 
habits of Western society. 
We conducted a study to assess the possible effects of SDG on serum lipid 
parameters and organ and total body weight gain in obese animals.  We fed a purified 
45% fat in rodent laboratory chow diet for five weeks to induce rats to an obese state. The 
literature suggests four weeks is sufficient to see significant changes in the desired 
parameters74,156.  However, as with my attempt to repeat our previous studies on the 
effects of flaxseed lignan on hypercholesterolemia, I had to order younger rats than 
originally planned. Following 4 weeks administration of a high fat diet, the animals on an 
obesity diet did not exhibit significant increases in body weight gain, organ weights or 
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significant elevations in serum cholesterol and triglyceride levels as compared with the 
control group; however, I did observe elevated retroperitoneal fat weights.  I used female 
Wistar rats to maintain consistency with previous studies on lignans.  I suspect our 
inability in induce an obese state could be due to the diet itself or the age of the animal.  
In a study of male Sprague-Dawley rats who were started on a 45% fat diet at 50-60 g 
(weanling age) did not show changes in body weight gain in comparison to a basal diet 
for the first 6 weeks of feeding and alterations in body weight were not viewed until the 
animals were over 300 g in body weight157.  Though this study used a different strain of 
rat, it suggests that younger animals are less susceptible to weight changes as a result of a 
45% fat purified diet. 
With respect to the diet, the literature reports rats fed a cafeteria type diet 
demonstrated significant changes in body weight following 2 weeks administration in 
both male and female Wistar rats of 4 weeks of age156.  The study is similar to my study 
except for the differences in the diets.  In my study, a purified high fat diet was used, 
whereas the reported study used a cafeteria type diet consisting of cookies, liver pate, 
bacon and chocolate among other high fat foods.  It can be speculated that a modified diet 
with 45% fat was less effective than the cafeteria diet in inducing changes in body 
weight, although the high fat diet did have some effects as indicated by the elevated 
retroperitoneal fat weights. The physiological changes found in the animals suggest that 
the diet was altering the body composition of the animals and with a longer feeding 
period, changes in body weight could have been observed.   
 The age of the animals used in the obesity study may offer a partial explanation 
for lack of statistically significant increases in body and organ weights and serum lipid 
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parameters. In my study, the animals were ordered at a smaller size due to unavailability 
of appropriately aged animals at the time. Though we were not able to see significant 
increases in body weight gain with 4 weeks treatment on a high fat diet, the increase in 
retroperitoneal fat suggests that the diet was causing physiological changes.  It may again 
be the case that the animals were not exposed to the diet at an age where they would be 
susceptible to such a diet, and that younger animals may be able to accommodate the 
higher fat levels. Though the study was unsuccessful for the evaluation of SDG on in a 
diet-induced obesity rat model, it stresses the importance of age as a factor in the 
induction of obesity and hyperlipidemia.   
 Hypertriglyceridemia is induced by the over consumption of simple sugars, 
mainly fructose.  Currently, the consumption of sweetened beverages is the main source 
of fructose in human diets158.  The high rate of consumption of fructose is of concern in 
children and is a contributing factor to childhood obesity159.  In our studies, it was found 
that hypertriglyceridemic male Sprague-Dawley rats did not have a significant increase in 
body weight gain following 2 weeks treatment, yet a significant increase in 
retroperitoneal adipose tissue weight with fructose feeding was observed, which confirms 
previous data collected using the same model147.  My study suggests that high dietary 
fructose is causing physiological changes within the animal, yet longer duration of 
fructose feeding may be required to observe changes in the rate of weight gain.  This 
information further supports evidence that consumption of beverages high in fructose 
contributes to childhood obesity.  
 Another contributing factor to childhood obesity is the consumption of fast-food 
and cafeteria type diets160.  In my study of female Wistar rats, I found that despite no 
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significant changes in body weight following 4 weeks consumption of a 45% fat diet, 
retroperitoneal fat stores were almost two fold higher.  Though our data do not confirm 
that of the present literature, where changes in the rate of body weight were observed 
with 4 weeks treatment, it provides further data to support the recommendation to 
decrease consumption of these types of foods, since excess dietary consumption of lipids 
is channeled into adipose storage depots in the body. 
Dietary manipulations to rodent models are affected by both the strain and sex of 
the animals used.  Male Sprague-Dawley rats are most often used in hypertriglyceridemic 
and hypercholesterolemic studies, whereas obesity diets are effective in male Sprague-
Dawley and Wistar rats, both out bred rodent strains.  Conflicting literature on the effects 
of flaxseed in rodent models forced my laboratory to conduct pilot studies to identify the 
appropriate rodent model. This pilot study and subsequent studies using 1% cholesterol in 
the diet steered my laboratory towards the use of the female Wistar rat. In all subsequent 
studies relating to the effects of flaxseed lignans on serum and hepatic lipid parameters, 
the female Wistar rat was first employed.  I found, however, that female Wistar rats were 
not induced to a hypertriglyceridemic state following 4 weeks administration of 10% 
fructose in water, 2 weeks longer than most studies that induced hypertriglyceridemia in 
the male Sprague-Dawley rat147.  To provide a model where we could investigate the 
potential effects of flaxseed lignans on hypertriglyceridemia, we performed the study in 
the established model of hypertriglyceridemia, the male Sprague-Dawley rats. I found 
that following 2 weeks treatment, the animals were induced to a hypertriglyceridemic 
state consistent with literature reports.  Further investigations to determine whether the 
differences were due to the strain or gender were not performed.    
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 In my thesis research, I planned to investigate the effects of flaxseed lignans on 
hyperlipidemic animals.  In general, I was unable to assess the effects of SDG on 
hypercholesterolemic or obese rats since my dietary manipulations failed to induce these 
disease states.  The differences in study design with respect to the method of induction 
for hyperlipidemia, strain, gender or age of the animals, as well as duration of treatment 
are all factors that may have contributed to my failed attempts to induce hyperlipidemia.  
Although disappointing from my perspective, my research does identify important study 
design issues not well-addressed in the literature. With further investigation of these 
different parameters, a more definitive result could be made with respect to flaxseed 
lignans and their effects on these hyperlipidemic states. 
 
5.4 Preliminary Safety Evaluation of Oral Administration of the Purified 
Flaxseed Lignan, SDG 
 Flax has been taken as a health food for many years with claims to alleviate a 
variety of disease states161.  Despite flax’s promotion, the safety of the consumption of its 
purified components has yet to be determined125.  Most of the research on flaxseed is 
focused on the mammalian metabolites of SDG, ED and EL. It is not clear at this time if 
the biologically active component of flaxseed is the plant lignans or their metabolites.  
Furthermore, flaxseed lignans occur in flaxseed in polymeric form complexed with 
glucoside moieties and other plant components. Purified components may exert different 
pharmacological properties when compared to consumption of its natural form.  
Consequently, we must exercise care when we extrapolate information on the effects of 
whole flaxseed to the purified components162. 
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An evaluation to assess the lignan effects in an animal model is important for 
understanding its efficacy and other potential effects.  Animal studies are important as 
they provide insight into tissue distribution and toxicity, which cannot be collected in 
human studies.  In my small safety study, I found that daily oral administration of SDG 
(4.4µmol/kg body weight) for four weeks caused no gross morphological changes in 
female Wistar juvenile rats. My findings are consistent with observations in Fisher 344 
rats exposed to 10% flaxseed supplemented diets from birth to 12 weeks of age, which 
reported no morphological changes in the organs and body condition parameters 
assessed125. The observations made in my study in conjunction with the study on Fisher 
344 rats suggest that 10% flaxseed supplemented diets and SDG at 4.4 µmol/kg do not 
produce grossly deleterious effects. 
Hematology and blood chemistry analysis also showed no changes with daily 
administration of SDG for four weeks in female Wistar rats, except in the red cell 
distribution width (RDW).  The values for RDW in both groups were within normal 
range (11-15), and the changes are not clinically relevant.  Similar analysis was 
performed on Fisher 344 rats that were fed 10% flaxseed supplemented laboratory chow, 
and plasma ALT (a marker for liver damage) levels were not altered125.  ALT is a 
cytosolic liver enzyme whose appearance in the blood signifies liver damage125.  In 
human healthy subjects, daily consumption of 32 g of flaxseed caused no changes in  
standard hematology and clinical chemistry test parameters such as hemoglobin and 
counts of red blood cells, white blood cells or neutrophils, and serum total bilirubin, 
aspartate aminotransferase, alkaline phosphatase, protein, albumin, glucose and urea, 
respectively163.  In this same study, a significant decrease in serum creatinine with 
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flaxseed consumption was observed, but the values remained within normal ranges.  
These studies confirm the results of my study suggesting that flaxseed consumption and 
its purified lignan, SDG, do not cause obvious toxicity to the liver, kidney and 
hemopoietic system in rodents and humans. Further investigations following long-term 
administration of SDG and at higher doses are needed to determine the full toxic potential 
of the purified flaxseed lignans.  
 
5.5 Preliminary Investigations into the IV and Oral Pharmacokinetics of 
Secoisolariciresinol, the Aglycone of SDG 
 A pharmacokinetic characterization is necessary to fully understand how a 
compound works in a biological system and to identify its potential therapeutic activity in 
vivo.  Currently, limited published information exists regarding the pharmacokinetics of 
SDG and SECO.  Partial studies evaluating SDG and its metabolites have been 
performed, but with the possibility of marketing purified lignan as a health food 
supplement, a full pharmacokinetic study where blood, urine, feces and bile are collected 
for at least 24 hours following a dose is warranted.  Most pharmacokinetic studies have 
principally focused on the metabolites of the plant lignans and their quantification in 
various biological fluids164-166. 
 It is also important to note that critical differences exist in the metabolic profiles 
of dietary flaxseed lignans when compared to the oral administration of purified plant 
lignans.  For example, following an oral bolus administration of SDG to rats, a greater 
proportion of the total dose is excreted as SECO in the urine as compared to rats fed 
dietary flaxseed164.  This suggests rats fed dietary flaxseed meal have enhanced 
 86
metabolism of the plant lignans to the mammalian lignans.  As well, significant 
differences in metabolite profiles are observed following oral administration of either 
SDG or SECO. With SECO administration, a greater proportion of the plant lignan was 
converted to the mammalian lignans167, with enterodiol as the major metabolite167. On the 
other hand, an oral dose of SDG resulted in a greater proportion of enterolactone 
production168.  The differences that result with the administration of the plant lignans in 
the glucoside or aglycone form or in its natural form stress the importance of evaluating 
each lignan to determine its efficacy and safety following an oral dose. 
 In my studies, I performed a pilot pharmacokinetic experiment where I evaluated 
plasma concentrations as a function of time following an IV and oral bolus dose of 
SECO.  I chose SECO to conduct preliminary pharmacokinetic studies, since it poses less 
complexity than its glucosidic form, SDG.  In flaxseed, SDG is the major lignan with 
SECO as its aglycone form169.  With oral administration of SDG, bacterial and/or 
intestinal β-glucosidase and β-glucuronidase likely cleave the glucoside groups from 
SDG prior to lignan permeation across the gastrointestinal mucosa169. With the glucoside 
groups attached to SDG, the molecules are polar, which likely prohibits absorption of 
SDG across the lipophilic membranes of the gastrointestinal wall. The aglycone form, 
SECO, is more lipophilic allowing its penetration across membranes and delivery into the 
portal circulation170.  Lignans not absorbed in the small intestine move down the 
digestive tract, where they undergo demethylation followed by dehydroxylation to 
produce the mammalian lignans ED and EL171.  Once absorbed, both the plant and 
mammalian lignans are extensively metabolized by phase II conjugation enzymes in the 
intestinal wall or the liver, and are subsequently excreted by the kidney or undergo 
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enterohepatic recirculation172.  In the systemic circulation, the lignans exist principally as 
conjugates of glucuronic acid or sulfate, yet little is known of the contributions of the 
intestine and the liver to first-pass metabolism. 
 Following an IV bolus dose of SECO at 10 mg/kg, I could monitor SECO plasma 
levels for only 30 minutes due to the limited analytical sensitivity of my HPLC method. 
Nevertheless, the data indicated an elimination half-life of 5 minutes and a distribution 
half-life of 26 seconds.  No other peaks suggestive of SECO metabolites appeared in the 
chromatograms.  Following an oral bolus of SECO at 10 mg/kg my analytical technique 
failed to detect plasma levels of SECO at any time points monitored up to 8 hours.  Lack 
of detectable levels of SECO has several possible explanations (e.g., very slow 
absorption kinetics and a large volume of distribution, very limited analytical sensitivity), 
but the most plausible reason for lack of detectable plasma levels following oral 
administration is poor bioavailability of SECO. Other investigators also found that 
following SDG or SECO single oral dose administration the urinary excretion of 
mammalian lignans and their metabolites constituted only a minor fraction of the total 
administered plant lignan 12-24 h post dose167,168,173. Only SECO and its metabolites 
were identified in urine and these were present at levels lower than the mammalian 
lignans134. One study showed that systemic recovery of radioactivity in body tissues 
represented no more than 6 % of the recovered dose by 12 h and 3% by 48 h173. 
Furthermore, several studies demonstrated that fecal excretion is the most significant 
excretion route for both the plant and mammalian lignans173,174. Such studies confirm my 
contention of poor oral bioavailability of SECO in the rat.  
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 The very rapid elimination half-life of SECO and the very limited oral 
bioavailability leads to speculation on which lignan form mediates the biological activity 
observed following chronic oral SDG and SECO administration in hypercholesterolemic 
rats. In studies where SDG was administered orally to rats, steady state mammalian 
lignan production was reached at 24 hours following a dose135.  This suggests a dose once 
a day is sufficient to maintain blood mammalian lignan concentrations. Furthermore, 
another study that evaluated the fecal activity following an oral dose of SDG found that 
chronic SDG administration relative to an acute dose results in a delay in fecal excretion 
of SDG175.  The authors suggested that this delay was due to enhanced enterohepatic 
recirculation of lignan metabolites.  A separate study also found increased beta-
glucuronidase activity in the colon and caecum of rats chronically fed SDG, offering 
further support that chronic SDG exposure increases enterohepatic recirculation169.    
 With the current knowledge available on SDG and SECO, a full pharmacokinetic 
study is warranted where blood, urine, feces and bile are collected for at least 24 hours 
following an oral and intravenous bolus dose.  The information gathered from these 
studies has provided interesting preliminary data needed to aid the design of a study that 
would be suitable for analysis of SDG and SECO and their metabolites.  
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6. Conclusions and Future Work 
 In my thesis research, I evaluated the effects of the purified flaxseed lignan, SDG, 
on animal models of hypertriglyceridemia, hypercholesterolemia and obesity.  Daily oral 
administration of SDG at physiological doses for four weeks to female Wistar rats fed 
regular laboratory rat chow did not alter rate of weight gain or change the daily food 
intake of the animals as compared to vehicle control rats. This suggests that in normal 
weight subjects, flaxseed lignans have no influence on food consumption and body 
weight parameters. 
In an established model of hypertriglyceridemia (10% fructose in water using 
male Sprague-Dawley rats), chronic oral administration of SDG failed to reduce both 
serum and hepatic triglyceride levels. This may indicate SDG has no protective effects in 
individuals consuming diets high in sugars.  However, I can not rule out the possibility 
that SDG may influence triglyceride metabolism in individuals consuming high fat diets 
or those who have a genetic predisposition towards hypertriglyceridemia. Although my 
studies failed to show any effects of SDG on hypercholesterolemia and obesity, previous 
studies in my laboratory and in the literature suggest the need for further studies on the 
potential hypolipidemic effects that result with lignan administration. 
My attempts to induce hypertriglyceridemia, hypercholesterolemia and obesity in 
female Wistar rats identified the importance of considering age, strain, and gender when 
using dietary manipulations to induce hyperlipidemic states. I found that dietary 
manipulations applied successfully to older rats could not induce hypercholesterolemia or 
obesity in rats of a younger age or of an alternative gender or strain.  Younger animals 
seem to be able to accommodate the dietary manipulations and I could not evaluate SDG 
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effects on either disease state.  It was noted that the animals fed a high fat diet showed 
larger retroperitoneal fat stores suggesting that the diet was causing physiological 
changes and, with a longer feeding period, the animals may have been induced to an 
obese state.  Furthermore, I noted differences in the ability to induce hypertriglyceridemia 
depending upon sex and strain of the rat. Conflicting data exist in the literature when 
gender and rat strain are considered. This speaks to a need to evaluate the underlying 
metabolic differences that account for gender and strain differences in diet-induced 
hyperlipidemic states. 
 A standard safety evaluation in female Wistar rats daily administered SDG (4.4 
µmol/kg) orally for 4 weeks found no changes in standard hematology and blood 
chemistry parameters.  Furthermore, no gross morphological changes in body condition 
or organs were found with animals administered SDG.  The results of this study suggest 
that SDG dosed at 4.4µmol/kg SDG per day for one month does not cause any untoward 
toxicological effects.  However, to fully appreciate the potential for SDG to cause 
toxicity, a more extensive investigation of SDG toxicity in vitro and in vivo is required. 
A pilot pharmacokinetic study indicated two-compartment kinetics following an 
IV bolus administration of SECO, with very rapid distribution and elimination phases. 
Following an oral bolus administration, plasma SECO levels were not detected, possibly 
indicating poor oral bioavailability. Since previous studies in our laboratory showed a 
marked pharmacological effect following once a day oral administration of SDG or 
SECO, my pilot pharmacokinetic study brings into question which lignan form is the 
biologically active form. A thorough pharmacokinetic investigation of the plant and 
mammalian lignans and their metabolites is warranted to more fully understand flaxseed 
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lignan efficacy and mechanism of action. As well, further understanding of the 
absorption, distribution, metabolism and excretion of lignans is pertinent for effectively 
assessing the safety of purified lignans. 
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